mutation_id	virus	genotype	gene	aa_change	Ganciclovir	Aciclovir	Cidofovir	Foscarnet	Brincidofovir	Letermovir	Brivudine	Penciclovir	Tomeglovir	Maribavir	Cyclopropavir	Amenamevir	Pritelivir	ref_title	ref_link	ref_doi	strain_generation	test_method	co_gene	co_aa	created_date	created_by	note	control_strain	status
1	HCMV	TOWNE	UL54	D301N	2.6		3	0.5										Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus	https://academic.oup.com/jid/article/188/1/32/821141	doi.org/10.1086/375743	Marker Transfer 	 PRA			17/11/2019	OJCharles			A
2	HCMV	AD169	UL54	C304S	1.3		1.4	1.1										Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/	doi.org/10.1016/j.jcv.2011.01.004	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
3	HCMV	TOWNE	UL54	N408D	4.9		5.6	1.3										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	 PRA			17/11/2019	OJCharles			A
4	HCMV	AD169	UL54	N408K	4.2		21	0.7										Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.	https://europepmc.org/article/pmc/pmc1797699	doi.org/10.1128/AAC.00633-06	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
5	HCMV	AD169	UL54	N408S	3.1		7.5	1										Novel DNA polymerase mutations conferring cytomegalovirus resistance: Input of BAC-recombinant phenotyping and 3D model	https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259	doi.org/10.1016/j.antiviral.2013.02.002	Recombinant BAC 	 PRA			17/11/2019	OJCharles			A
6	HCMV	TOWNE	UL54	N410K	2.9		3	0.8										Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus	https://academic.oup.com/jid/article/188/1/32/821141	doi.org/10.1086/375743	Marker Transfer 	 PRA			17/11/2019	OJCharles			A
7	HCMV	TOWNE	UL54	F412C	4.2		18	1.2										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	 PRA			17/11/2019	OJCharles			A
8	HCMV	AD169	UL54	F412L	4.6		9.4	1.1										Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/	doi.org/10.1016/j.jcv.2011.01.004	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
9	HCMV	AD169	UL54	F412S	5.3		13	0.8										Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/	doi.org/10.1016/j.jcv.2011.01.004	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
10	HCMV	TOWNE	UL54	F412V	4.3		15.5	1.1										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	 PRA			17/11/2019	OJCharles			A
11	HCMV	AD169	UL54	D413A	6.5		11	0.8										Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients	www.sciencedirect.com/science/article/pii/S1386653206004161	doi.org/10.1016/j.jcv.2006.11.005	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
12	HCMV	TOWNE	UL54	D413E	4.8		4.3	0.8										Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus	https://academic.oup.com/jid/article/188/1/32/821141	doi.org/10.1086/375743	Marker Transfer 	 PRA			17/11/2019	OJCharles			A
13	HCMV	AD169	UL54	D413N	3.8		10	1										Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/	doi.org/10.1128/AAC.03214-14	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
14	HCMV	Susceptible Clinical Isolate	UL54	P488R	3.5		7.9	0.6										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/	doi.org/10.1128/AAC.00334-11	Isolated strain	PRA			17/11/2019	OJCharles			A
15	HCMV		UL54	N495K	1.1		1.1	3.4										A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet	https://journals.sagepub.com/doi/abs/10.1177/135965350601100416	doi.org/10.1177/1359653506011004	Lab derived mutant 	PRA or SEAP			17/11/2019	OJCharles			A
16	HCMV	AD169	UL54	K500N	3.2		3	1.2										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA			17/11/2019	OJCharles			A
17	HCMV	TOWNE	UL54	L501I	6		9.1	1.4										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA			17/11/2019	OJCharles			A
18	HCMV	TOWNE	UL54	T503I	2.9		6.1	0.5										Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus	https://academic.oup.com/jid/article/188/1/32/821141	doi.org/10.1086/375743	Marker Transfer 	PRA			17/11/2019	OJCharles			A
19	HCMV	AD169	UL54	A505V	1.8		2	1.1										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://academic.oup.com/jid/article/209/8/1219/831553	doi.org/10.1093/infdis/jit654	Lab derived mutant 	PRA or SEAP			17/11/2019	OJCharles	minor disparity in fold change ref - rev. ignoring Rev using original reference only		A
20	HCMV	TOWNE	UL54	K513E	5		9.1	1.4										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA			17/11/2019	OJCharles			A
21	HCMV	AD169	UL54	K513N	6		12.5	1.5										A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture	https://www.sciencedirect.com/science/article/pii/S0042682298992996	doi.org/10.1006/viro.1998.9299	Marker Transfer 	PRA			17/11/2019	OJCharles			A
22	HCMV	AD169	UL54	K513N	9.8		34	3										A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture	https://www.sciencedirect.com/science/article/pii/S0042682298992996	doi.org/10.1006/viro.1998.9299	Marker Transfer 	PRA	UL54	V812L	17/11/2019	OJCharles			A
23	HCMV	AD169	UL54	K513R	3.7		10	1.1										Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/	doi.org/10.1128/AAC.03214-14	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
24	HCMV	Clinical Isolate	UL54	D515E	2.7			4.6										Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes	https://ashpublications.org/blood/article/96/9/3286/181219/Drug-resistant-human-cytomegalovirus-infection-in?searchresult=1	doi.org/10.1182/blood.V96.9.3286	Lab derived mutant 	PRA or SEAP	UL54	L516M;I521T	17/11/2019	OJCharles			A
25	HCMV	TOWNE	UL54	D515G	1		1	1.2										Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus	https://academic.oup.com/jid/article/188/1/32/821141	doi.org/10.1086/375743	Marker Transfer 	PRA			16/03/2020	OJCharles			A
26	HCMV	Clinical Isolate	UL54	D515Y	6.2		0.9	4.7										Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis	https://www.sciencedirect.com/science/article/pii/S0166354216300365	doi.org/10.1016/j.antiviral.2016.02.004	Recombinant BAC 	GFP fluorescence reduction assay			23/11/2020	OJCharles			A
27	HCMV	TOWNE	UL54	L516R	2.1		5.1	0.8										Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus	https://academic.oup.com/jid/article/188/1/32/821141	doi.org/10.1086/375743	Marker Transfer 	PRA			17/11/2019	OJCharles			A
28	HCMV		UL54	I521T	2.1		5.1	0.8										Rev. Med. Virol. 2016; 26: 161-182			Lab derived mutant 	PRA or SEAP			17/11/2019	OJCharles	Unable to substantiate review values from their references		O
29	HCMV	AD169	UL54	I521T	3		3.9	1										Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus	http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf	doi.org/10.1016/j.jcv.2008.04.005.	Marker Transfer 	SEAP			16/03/2020	OJCharles		AD169	A
30	HCMV	AD169	UL54	P522A	3		4.1	1										Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus	http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf	doi.org/10.1016/j.jcv.2008.04.005.	Marker Transfer 	SEAP			17/11/2019	OJCharles		AD169	A
31	HCMV	AD169	UL54	P522L	1.3		1.2	1.4										Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus	http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf	doi.org/10.1016/j.jcv.2008.04.005.	Marker Transfer 	SEAP			16/03/2020	OJCharles		AD169	A
32	HCMV	TOWNE	UL54	P522S	3.1		3.6	1.1										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA			17/11/2019	OJCharles			A
33	HCMV	AD169	UL54	del524	3.5		9.7	1.1										Novel DNA polymerase mutations conferring cytomegalovirus resistance: Input of BAC-recombinant phenotyping and 3D model	https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259	doi.org/10.1016/j.antiviral.2013.02.002	Recombinant BAC 	PRA			17/11/2019	OJCharles			A
34	HCMV	AD169	UL54	V526L	5.5		2.5	1.8										Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/	doi.org/10.1128/jcm.02205-14	Recombinant BAC 	GLuc reporter assay			23/11/2020	OJCharles			A
35	HCMV	AD169	UL54	C539G	3.1		4.4	1										Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/	doi.org/10.1128/AAC.03214-14					17/11/2019	OJCharles			A
36	HCMV	Susceptible Clinical Isolate	UL54	C539R	3.2		13.3	0.7										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Isolated strain	PRA			17/11/2019	OJCharles			A
37	HCMV		UL54	D542E	1.5		12	1.7										Selection and Recombinant Phenotyping of a Novel CMX001 and Cidofovir Resistance Mutation in Human Cytomegalovirus	https://aac.asm.org/content/57/7/3321	doi.org/10.1128/AAC.00062-13	Recombinant BAC 	PRA			23/11/2020	OJCharles			A
38	HCMV	AD169	UL54	V544A	1		1.1	0.9										Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/	doi.org/10.1016/j.jcv.2011.01.004	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
39	HCMV	TOWNE	UL54	L545S	3.5		9.1	1.2										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA			17/11/2019	OJCharles			A
40	HCMV	AD169	UL54	L545W	4.9		6.3	1.3										Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/	doi.org/10.1016/j.jcv.2011.01.004	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
41	HCMV	AD169	UL54	T552N	1.9		1.2	2.6										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA			17/11/2019	OJCharles			A
42	HCMV	AD169	UL54	Q578H	3.3		2.3	4.5										Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/	doi.org/10.1016/j.jcv.2011.01.004	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
43	HCMV	AD169	UL54	S585A	1.5		1.4	2.7										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA			17/11/2019	OJCharles			A
44	HCMV	TOWNE	UL54	D588E	1.3		1.1	2.3										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA			17/11/2019	OJCharles			A
45	HCMV	AD169	UL54	D588N	2		1.3	2.8										Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/	doi.org/10.1016/j.jcv.2011.01.004	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
46	HCMV		UL54	D588N	3.8		2.7	9										Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity	https://www.sciencedirect.com/science/article/pii/S1386653201001603	doi.org/10.1016/S1386-6532(01)00160-3	Lab derived mutant 	PRA or SEAP			17/11/2019	OJCharles			A
47	HCMV	Susceptible Clinical Isolate	UL54	F595I	1.3		1.2	2										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Isolated strain	PRA			17/11/2019	OJCharles			A
48	HCMV	TOWNE	UL54	A692S	1.6		1.7	3.3										Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus	https://academic.oup.com/jid/article/188/1/32/821141	doi.org/10.1086/375743	Marker Transfer 	PRA			16/03/2020	OJCharles			A
49	HCMV	Clinical Isolate	UL54	T700A	1.2		1.3	5.8										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA			17/11/2019	OJCharles			A
50	HCMV	AD169	UL54	A714V	0.8		0.7	0.8										Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/	doi.org/10.1016/j.jcv.2011.01.004	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
51	HCMV		UL54	V715M	1.3		1.1	9.5										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA			17/11/2019	OJCharles			A
52	HCMV		UL54	V715M	1		1.1	5.5										Rev. Med. Virol. 2016; 26: 161-182			Lab derived mutant 	PRA or SEAP			17/11/2019	OJCharles	Unable to substantiate review values from their references		O
53	HCMV	AD169	UL54	I726V	1.9		1.9	1.2										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			17/11/2019	OJCharles			A
54	HCMV	TOWNE	UL54	E756D	1.2		0.7	3.4										Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus	https://academic.oup.com/jid/article/188/1/32/821141	doi.org/10.1086/375743	Marker Transfer 	PRA			17/11/2019	OJCharles			A
55	HCMV	AD169	UL54	E756K	8.1		2.7	8										Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/	doi.org/10.1128/jcm.02205-14	Recombinant BAC 	GLuc reporter assay			23/11/2020	OJCharles			A
56	HCMV	TOWNE	UL54	E756Q	1.7		1	4.3										Mutations Conferring Foscarnet Resistance in A Cohort of Patients with Acquired Immunodeficiency Syndrome and Cytomegalovirus Retinitis	https://academic.oup.com/jid/article/187/5/777/2191368	doi.org/10.1086/368385	Marker Transfer 	PRA			23/11/2020	OJCharles			A
57	HCMV	AD169	UL54	L773V	3		2.5	4.4										Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/	doi.org/10.1128/AAC.03214-14	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
58	HCMV	AD169	UL54	L776M	2.5		1	3.5										Artesunate as a Potent Antiviral Agent in a Patient with Late Drug-Resistant Cytomegalovirus Infection after Hematopoietic Stem Cell Transplantation	https://academic.oup.com/cid/article/46/9/1455/330370	doi.org/10.1086/587106	Marker Transfer 	PRA			23/11/2020	OJCharles			A
59	HCMV	TOWNE	UL54	V781I	1		1.2	5.2										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA			17/11/2019	OJCharles			A
60	HCMV		UL54	V787A	4.7		0.7	3.2										Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis	https://www.sciencedirect.com/science/article/pii/S0166354216300365	doi.org/10.1016/j.antiviral.2016.02.004	Recombinant BAC 	GFP fluorescence reduction assay			23/11/2020	OJCharles			A
61	HCMV	TOWNE	UL54	V787L	2.4		1	4.1										Mutations Conferring Foscarnet Resistance in A Cohort of Patients with Acquired Immunodeficiency Syndrome and Cytomegalovirus Retinitis	https://academic.oup.com/jid/article/187/5/777/2191368	doi.org/10.1086/368385	Marker Transfer 	PRA			23/11/2020	OJCharles			A
62	HCMV	TOWNE	UL54	L802M	1.1		0.9	3.2										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA			17/11/2019	OJCharles			A
63	HCMV	AD169	UL54	L802V	1.8		1.1	0.9										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA			17/11/2019	OJCharles			A
64	HCMV	TOWNE	UL54	K805Q	1		2.2	0.18										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA			17/11/2019	OJCharles			A
65	HCMV	AD169	UL54	A809V	2.4		1.9	3.3										Growth and Drug Resistance Phenotypes Resulting from Cytomegalovirus DNA Polymerase Region III Mutations Observed in Clinical Specimens	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151462/	doi.org/10.1128/AAC.00736-07	Recombinant BAC 	SEAP			23/11/2020	OJCharles			A
66	HCMV	AD169	UL54	A809V				3.6										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
67	HCMV	AD169	UL54	V812L	2.5		3.2	2.9										A  Point  Mutation  in  the  Human  Cytomegalovirus  DNA  Polymerase  Gene  Selectedin  Vitroby  Cidofovir  Confers  a  Slow  Replication  Phenotype  in  Cell  Culture	https://www.sciencedirect.com/science/article/pii/S0042682298992996	doi.org/10.1006/viro.1998.9299	Marker Transfer 	PRA			23/11/2020	OJCharles			A
68	HCMV	AD169	UL54	T813S	2.5		2.7	4.9										Growth and Drug Resistance Phenotypes Resulting from Cytomegalovirus DNA Polymerase Region III Mutations Observed in Clinical Specimens	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151462/	doi.org/10.1128/AAC.00736-07	Recombinant BAC 	SEAP			23/11/2020	OJCharles			A
69	HCMV	TOWNE	UL54	T821I	4.5		1.9	21										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA			17/11/2019	OJCharles			A
70	HCMV	AD169	UL54	P829S	2		1.6	1.1										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA			17/11/2019	OJCharles			A
71	HCMV	AD169	UL54	A834P	5.4		3	6.4										Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.	https://europepmc.org/article/pmc/pmc1797699	doi.org/10.1128/AAC.00633-06	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
72	HCMV	AD169	UL54	A834P	22.7		18.8	7.2										Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.	https://europepmc.org/article/pmc/pmc1797699	doi.org/10.1128/AAC.00633-06	Recombinant BAC 	SEAP	UL54	N408K	17/11/2019	OJCharles			A
73	HCMV	TOWNE	UL54	T838A	1.8		0.8	2.4										How Evolution of Mutations Conferring Drug Resistance Affects Viral Dynamics and Clinical Outcomes of Cytomegalovirus-Infected Hematopoietic Cell Transplant Recipients	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC540138/	doi.org/10.1128/JCM.43.1.208-213.2005	Marker Transfer 	PRA			23/11/2020	OJCharles			A
74	HCMV	AD169	UL54	G841A	3.2		2.6	4.3										Growth and Drug Resistance Phenotypes Resulting from Cytomegalovirus DNA Polymerase Region III Mutations Observed in Clinical Specimens	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151462/	doi.org/10.1128/AAC.00736-07	Recombinant BAC 	SEAP			23/11/2020	OJCharles			A
75	HCMV	AD169	UL54	M844T	1.4		1.3	2.5										Cyclopropavir Susceptibility of Cytomegalovirus DNA Polymerase Mutants Selected after Antiviral Drug Exposure	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256009/	doi.org/10.1128/AAC.05559-11	Lab derived mutant 	PRA or SEAP			23/11/2020	OJCharles			A
76	HCMV	AD169	UL54	M844V	2.3		1.6	2.2										Cyclopropavir Susceptibility of Cytomegalovirus DNA Polymerase Mutants Selected after Antiviral Drug Exposure	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256009/	doi.org/10.1128/AAC.05559-11	Lab derived mutant 	PRA or SEAP			23/11/2020	OJCharles			A
77	HCMV	Susceptible Clinical Isolate	UL54	L862F	1.7		0.9	1.1										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Isolated strain	PRA			17/11/2019	OJCharles			A
78	HCMV	Susceptible Clinical Isolate	UL54	V946L	1.1		0.9	2.4										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Isolated strain	PRA			17/11/2019	OJCharles			A
79	HCMV	AD169	UL54	L957F	2.7		1.4	1.3										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA			17/11/2019	OJCharles			A
80	HCMV	TOWNE	UL54	G971D	1.4		1	1.2										Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus	https://academic.oup.com/jid/article/188/1/32/821141	doi.org/10.1086/375743	Marker Transfer 	PRA			16/03/2020	OJCharles			A
81	HCMV	TOWNE	UL54	del981-982	8.3		2.8	3.6										Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus	https://academic.oup.com/jid/article/188/1/32/821141	doi.org/10.1086/375743	Marker Transfer 	PRA			23/11/2020	OJCharles			A
82	HCMV	AD169	UL54	A987G	5.1		4.5											Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
83	HCMV	TOWNE	UL54	A987G	5.3		11.3	1.2										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA			17/11/2019	OJCharles			A
84	HCMV	Susceptible Clinical Isolate	UL54	L802M	1.7		1	2.7										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Isolated strain	PRA			17/11/2019	OJCharles			A
85	HCMV	Susceptible Clinical Isolate	UL54	P488R	7.5		7.4	1										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Isolated strain	PRA			17/11/2019	OJCharles			A
86	HCMV	Susceptible Clinical Isolate	UL54	C539R	6.3													Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Isolated strain	PRA			17/11/2019	OJCharles			A
87	HCMV	Susceptible Clinical Isolate	UL54	C539R	59		7.4											Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Isolated strain	PRA	UL97	H520Q	17/11/2019	OJCharles			A
88	HCMV	Susceptible Clinical Isolate	UL54	C539R;F595I	28													Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Isolated strain	PRA	UL97	G598D	17/11/2019	OJCharles			A
89	HCMV	Susceptible Clinical Isolate	UL54	C539R; F595I	79		13	6.3										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Isolated strain	PRA	UL97	H520Q	17/11/2019	OJCharles			A
90	HCMV	TOWNE	UL54	S676G	1.1		1.2	0.9										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA			16/03/2020	OJCharles			A
91	HCMV	TOWNE	UL54	V759M	1.5		1.1	1.1										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA			16/03/2020	OJCharles			A
92	HCMV	TOWNE	UL54	F412C	6.2		16	3.1										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA	UL54	L802M	16/03/2020	OJCharles			A
93	HCMV	TOWNE	UL54	K513E	6.6		11.1	2.7										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA	UL54	D558E	16/03/2020	OJCharles			A
94	HCMV	TOWNE	UL54	K805Q	4.3		2.1	10.1										Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/	doi.org/10.1128/jvi.72.7.5927-5936.1998	Marker Transfer 	PRA	UL54	T821I	16/03/2020	OJCharles			A
95	HCMV	AD169	UL54	L545S	5		11.9	1										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
96	HCMV	AD169	UL54	D879G	1.2		0.9	0.9										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
97	HCMV	AD169	UL54	L545S	7.3		4.5	1.8										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA	UL54	P829S	16/03/2020	OJCharles			A
98	HCMV	AD169	UL54	N408D	4		4.2	1.3										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
99	HCMV	AD169	UL54	N408D	4.2		1.9	4										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA	UL54	T552N	16/03/2020	OJCharles			A
100	HCMV	AD169	UL54	N408D	4.9		4.5	3.3										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA	UL54	L957F	16/03/2020	OJCharles			A
101	HCMV	AD169	UL54	T552N	1.6		0.9	5.5										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA	UL54	L957F	16/03/2020	OJCharles			A
102	HCMV	AD169	UL54	N757K	1.3		0.8	1.3										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
103	HCMV	AD169	UL54	L802M	1.7		1	2.7										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
104	HCMV	AD169	UL54	L926V	1.3		1.1	0.9										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
105	HCMV	AD169	UL54	K500N	2.4		2.4	2.7										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Recombinant BAC 	PRA	UL54	S585A	16/03/2020	OJCharles			A
106	HCMV	Susceptible Clinical Isolate	UL54	V787L	1.8		0.9	2.4										Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet	https://journals.asm.org/doi/10.1128/aac.00334-11	doi.org/10.1128/aac.00334-11	Isolated strain	PRA			16/03/2020	OJCharles			A
107	HCMV	AD169	UL97	del590-593	4.8		1											New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/	doi.org/10.1128/AAC.49.12.4860-4866.2005	Lab derived mutant 	PRA			16/03/2020	OJCharles			A
108	HCMV	AD169	UL54	L545S	7.4		16	1.5										New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/	doi.org/10.1128/AAC.49.12.4860-4866.2005	Lab derived mutant 	PRA			16/03/2020	OJCharles			A
109	HCMV	AD169	UL54	L545S	16		6.5	1.3										New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/	doi.org/10.1128/AAC.49.12.4860-4866.2005	Lab derived mutant 	PRA	UL97	M460I	16/03/2020	OJCharles			A
110	HCMV	AD169	UL54	T552N	3.2		2.1	5.8										New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/	doi.org/10.1128/AAC.49.12.4860-4866.2005	Lab derived mutant 	PRA			16/03/2020	OJCharles			A
111	HCMV	TOWNE	UL54	L737M	1.1		2	1										Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.	https://europepmc.org/article/pmc/pmc1797699	doi.org/10.1128/AAC.00633-06	Marker Transfer 	PRA			16/03/2020	OJCharles			A
112	HCMV	TOWNE	UL54	A834P	6.1		6	7.7										Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.	https://europepmc.org/article/pmc/pmc1797699	doi.org/10.1128/AAC.00633-06	Marker Transfer 	PRA			16/03/2020	OJCharles			A
113	HCMV	AD169	UL54	Q229K	1.2		1	1.2										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
114	HCMV	AD169	UL54	D247N	0.9		0.9	1.3										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
115	HCMV	AD169	UL54	D262N	1.1		1	1.2										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
116	HCMV	AD169	UL54	T271A	1		0.7	0.9										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
117	HCMV	AD169	UL54	V284E	1.2		1.1	1.2										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
118	HCMV	AD169	UL54	D288N	1.2		1.2	1.2										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
119	HCMV	AD169	UL54	F396L	1.4		0.9	0.9										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
120	HCMV	AD169	UL54	L424V	1.3		1.3	1.2										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
121	HCMV	AD169	UL54	T437M	1		1	0.8										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
122	HCMV	AD169	UL54	F460L	1.2		1.2	1.2										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
123	HCMV	AD169	UL54	A505V	1.9		1.9	1										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
124	HCMV	AD169	UL54	A543S	1		1	1										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
125	HCMV	AD169	UL54	S612N	0.9		1	0.7										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
126	HCMV	AD169	UL54	V654G	1.1		1.1	1.1										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
127	HCMV	AD169	UL54	S660G	1		0.9	1.1										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
128	HCMV	AD169	UL54	S660N	1.2		1	0.8										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
129	HCMV	AD169	UL54	G667N	0.9		0.8	1										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
130	HCMV	AD169	UL54	A692G	0.8		0.9	1										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
131	HCMV	AD169	UL54	I726T	2		1.7	1.1										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
132	HCMV	AD169	UL54	E793V	0.9		0.7	1.1										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
133	HCMV	AD169	UL54	Q795P	0.9		0.9	1.1										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
134	HCMV	AD169	UL54	Q795R	1		0.9	1										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
135	HCMV	AD169	UL54	G841S	2.2		1.1	2.1										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
136	HCMV	AD169	UL54	P859A	0.8		1	0.8										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
137	HCMV	AD169	UL54	V902G	1.2		1	1										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
138	HCMV	AD169	UL54	E903G	1.1		1	0.9										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
139	HCMV	AD169	UL54	K947E	1		1	1.1										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
140	HCMV	AD169	UL54	M959T	1.2		0.9	1.2										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
141	HCMV	AD169	UL54	N345S	1.2		0.7	0.9										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
142	HCMV	AD169	UL54	V476G	0.9		0.8	0.4										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
143	HCMV	AD169	UL54	Q578L	1.9		0.8	3										Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/	doi.org/10.1093/infdis/jit654	Recombinant BAC 	PRA			16/03/2020	OJCharles			A
144	HCMV		UL97	D605E	Polymorphism													Rev. Med. Virol. 2016; 26: 161-182			Lab derived mutant 	PRA or SEAP			17/11/2019	OJCharles	Typo?		O
148	HCMV		UL97	L405P	2.5													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
149	HCMV		UL97	D456N	12													Rev. Med. Virol. 2016; 26: 161-182			Lab derived mutant 	PRA or SEAP			17/11/2019	OJCharles	Review value does not match reference		O
150	HCMV	Clinical Isolate	UL97	M460I	2.2		1	1										Analysis and Characterization of Antiviral Drugâ€“Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients	https://academic.oup.com/jid/article/186/6/760/2191110	doi.org/10.1086/342844	Isolated strain 	PRA			07/08/2023	OJCharles			A
151	HCMV	AD169	UL97	M460T	9.3													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
152	HCMV	AD169	UL97	M460V	8.3													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
153	HCMV		UL97	V466G	3.5													Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis	https://www.sciencedirect.com/science/article/abs/pii/S1386653210000181	doi.org/10.1016/j.jcv.2010.01.009	Recombinant BAC 	PRA			17/11/2019	OJCharles			A
155	HCMV	AD169	UL97	C518Y	12													A new mutation in the human cytomegalovirus UL97 gene may confer ganciclovir resistance in Chinese kidney transplant recipients	https://link.springer.com/article/10.1007/s00705-012-1479-4	doi.org/10.1007/s00705-012-1479-4	Marker Transfer	PRA			17/11/2019	OJCharles		AD169	A
161	HCMV	Towne	UL97	A591V	1.3													Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir	https://academic.oup.com/jid/article/185/2/162/2191141	doi.org/10.1086/338362	Marker Transfer 	PRA			17/11/2019	OJCharles		Towne	A
164	HCMV	AD169	UL97	C592G	4.05													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
165	HCMV	AD169	UL97	A594E	3													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
166	HCMV	AD169	UL97	A594G	13.5													Value of a ligase chain reaction assay for detection of ganciclovir resistance-related mutation 594 in UL97 gene of human cytomegalovirus	https://linkinghub.elsevier.com/retrieve/pii/S0166-0934(97)00093-1	doi.org/10.1016/S0166-0934(97)00093-1	Marker Transfer	PRA			17/11/2019	OJCharles		AD169	A
168	HCMV	Towne	UL97	A594T	2.7													Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir	https://academic.oup.com/jid/article/185/2/162/2191141	doi.org/10.1086/338362	Marker Transfer 	PRA			17/11/2019	OJCharles		Towne	A
169	HCMV	AD169	UL97	A594V	6.4													Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/	doi.org/10.1128/jcm.02205-14	Recombinant BAC 	GLuc reporter assay			23/11/2020	OJCharles			A
170	HCMV	AD169	UL97	L595F	11.4													Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/	doi.org/10.1128/jcm.02205-14	Recombinant BAC 	GLuc reporter assay			23/11/2020	OJCharles			A
171	HCMV		UL97	L595S	5.5													Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma	https://www.jci.org/articles/view/117648	doi.org/10.1172/jci117648	Isolated strain 	PRA			17/11/2019	OJCharles			A
172	HCMV	Towne	UL97	L595W	5.1													Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir	https://academic.oup.com/jid/article/185/2/162/2191141	doi.org/10.1086/338362	Marker Transfer 	PRA			17/11/2019	OJCharles		Towne	A
174	HCMV	Towne	UL97	del595-603	8.4													A Nine-Codon Deletion Mutation in the Cytomegalovirus UL97 Phosphotransferase Gene Confers Resistance to Ganciclovir	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC89650	doi.org/10.1128/aac.44.1.183-185.2000	Marker Transfer 	PRA			17/11/2019	OJCharles		Towne	A
176	HCMV	Towne	UL97	E596G	2.3													Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir	https://academic.oup.com/jid/article/185/2/162/2191141	doi.org/10.1086/338362	Marker Transfer 	PRA			17/11/2019	OJCharles		Towne	A
177	HCMV	TB40	UL97	E596Y	6.4													Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay	https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759	doi.org/10.1016/j.jcv.2015.06.090	Recombinant BAC	PRA			17/11/2019	OJCharles		TB40	A
180	HCMV	Clinical Isolate	UL97	K599T	5.3													Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant	https://www.sciencedirect.com/science/article/abs/pii/S0166354298000515	doi.org/10.1016/S0166-3542(98)00051-5	Isolated strain 	PRA			17/11/2019	OJCharles		AD169	A
181	HCMV	Towne	UL97	del600	1.9													Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir	https://academic.oup.com/jid/article/185/2/162/2191141	doi.org/10.1086/338362	Marker Transfer 	PRA			17/11/2019	OJCharles		Towne	A
183	HCMV		UL97	C603R	3.6													Rev. Med. Virol. 2016; 26: 161-182			Lab derived mutant 	PRA or SEAP			17/11/2019	OJCharles	Review value does not match reference ref51 has no useable data ref61 is in here with a different ratio and ref65 has a different ratio too with an unusable datapoint		O
184	HCMV	AD169	UL97	C603S	1.9													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
185	HCMV	AD169	UL97	C603W	7.9													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
186	HCMV		UL97	C607F	1.9													Rev. Med. Virol. 2016; 26: 161-182			Lab derived mutant 	PRA or SEAP			17/11/2019	OJCharles	Cannot find value 1.9 in references ref72 does no tests ref77 no tests. Following ref trail leads to nowhere concrete		O
187	HCMV		UL97	C607Y	12.5													The Cys607â†’Tyr Change in the UL97 Phosphotransferase Confers Ganciclovir Resistance to Two Human Cytomegalovirus Strains Recovered from Two Immunocompromised Patients	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC105432/	doi.org/10.1128/aac.42.2.444	Marker Transfer	PRA			17/11/2019	OJCharles		AD169	A
188	HCMV		UL97	I610T	2.8													Rev. Med. Virol. 2016; 26: 161-182			Lab derived mutant 	PRA or SEAP			17/11/2019	OJCharles	typ0 2.8 should be 2.6?		O
189	HCMV	TB40	UL97	A613V	2.3													Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation	https://www.sciencedirect.com/science/article/abs/pii/S0166354213002866	doi.org/10.1016/j.antiviral.2013.09.026	Recombinant BAC	PRA			17/11/2019	OJCharles		TB40	A
191	HCMV	AD169	UL97	E655K	1.7													Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/	doi.org/10.1128/jcm.02205-14	Recombinant BAC 	GLuc reporter assay			23/11/2020	OJCharles			A
192	HCMV	AD169	UL89	D344E						1.8			1.7					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-17	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
193	HCMV	AD169	UL89	C347S						0.6			0.3					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-18	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
194	HCMV	AD169	UL89	R351H						0.7			0.4					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-19	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
195	HCMV	AD169	UL56	E769D						1			0.8					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-20	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
196	HCMV	AD169	UL56	Q204R						1.5			2.7					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-21	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
197	HCMV	AD169	UL56	Q204R						2.5			5.8					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-22	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP	UL89	D344E	17/11/2019	OJCharles			A
198	HCMV	AD169	UL56	N232Y						17			2.7					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-23	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
199	HCMV	AD169	UL56	K258E						14			0.3					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-24	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
200	HCMV	AD169	UL56	F261L						2.5			1					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-25	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
201	HCMV	AD169	UL56	F261L						4.8			2.1					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-26	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP	UL89	D344E	17/11/2019	OJCharles			A
202	HCMV	AD169	UL56	M329T						4.5			1.1					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-27	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
203	HCMV	AD169	UL56	M329T						8			2.2					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-28	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP	UL89	D344E	17/11/2019	OJCharles			A
204	HCMV	AD169	UL56	E237D						16			0.3					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-29	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
205	HCMV	AD169	UL56	E237D						34			0.6					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-30	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP	UL89	D344E	17/11/2019	OJCharles			A
206	HCMV	AD169	UL89	N320H						1.8			6.5					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-31	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
207	HCMV	AD169	UL89	M359I						1.5			7.4					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-32	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
208	HCMV	AD169	UL89	I334V						1.1			0.9					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-33	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
209	HCMV	AD169	UL89	N329S						2			15					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-34	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
210	HCMV	AD169	UL89	T350M						2.8			8.7					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-35	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
211	HCMV	AD169	UL89	V362M						1.2			98					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-36	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
212	HCMV	AD169	UL89	H389N						1.1			29					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-37	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
213	HCMV	AD169	UL89	N405D						1			15					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-38	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
214	HCMV	AD169	UL89	I334V						1.2			12					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-39	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP	UL89	N405D	17/11/2019	OJCharles			A
215	HCMV	AD169	UL56	L208M						0.8			3.4					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-40	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
216	HCMV	AD169	UL56	E407D						1.3			6					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-41	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
217	HCMV	AD169	UL56	H637Q						0.9			2					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-42	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
218	HCMV	AD169	UL56	V639M						1			10					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-43	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
219	HCMV	AD169	UL56	H637Q						1.2			17					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-44	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP	UL56	V639M	17/11/2019	OJCharles			A
220	HCMV	AD169	UL56	L764M						1.1			0.4					Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-45	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
221	HCMV	AD169	UL54	del981-982	7.3		3.8	3.1										New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir	https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf	doi.org/10.1128/AAC.00922-18	Recombinant BAC 	SEAP			16/03/2020	OJCharles		AD169	A
222	HCMV	AD169	UL56	C25F						5.4								New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir	https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf	doi.org/10.1128/AAC.00922-18	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
223	HCMV	AD169	UL56	L51M						0.8								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
224	HCMV	AD169	UL56	S229F						1.8								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
225	HCMV	AD169	UL56	V231A						2.1								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
226	HCMV	AD169	UL56	V231L						5.1								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
227	HCMV		UL56	N232Y						17								Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds	https://aac.asm.org/content/61/11/e01325-17.short	doi.org/10.1128/AAC.01325-17	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
228	HCMV	AD169	UL56	V236A						2.9								New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir	https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf	doi.org/10.1128/AAC.00922-18	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
229	HCMV	AD169	UL56	V236L						14								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
230	HCMV	AD169	UL56	V236M						32								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
231	HCMV	AD169	UL56	E237D						10								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
232	HCMV	AD169	UL56	L241P						96								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
233	HCMV	AD169	UL56	T244K						3.3								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
234	HCMV		UL56	L254F						3.2								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
235	HCMV	AD169	UL56	L257F						8.6								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
236	HCMV	AD169	UL56	L257I						4.9								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
238	HCMV	AD169	UL56	F261C						4.4								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
239	HCMV	AD169	UL56	F261L						2.8								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
240	HCMV	AD169	UL56	Y321C						4.6								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
241	HCMV	AD169	UL56	C325F						3000								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
242	HCMV	AD169	UL56	C325R						3000								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
243	HCMV	AD169	UL56	C325Y						3000								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
244	HCMV	AD169	UL56	C325W						9300								New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir	https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf	doi.org/10.1128/AAC.00922-18	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
245	HCMV	AD169	UL56	L328V						1.9								New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir	https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf	doi.org/10.1128/AAC.00922-18	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
246	HCMV	AD169	UL56	M329T						4.4								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
247	HCMV	AD169	UL56	A365S						2								New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir	https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf	doi.org/10.1128/AAC.00922-18	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
248	HCMV	AD169	UL56	N368D						2								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
249	HCMV	AD169	UL56	V231L						5								Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure	https://aac.asm.org/content/aac/58/1/610.full.pdf	doi.org/10.1128/AAC.01794-13	Recombinant BAC 	GFP fluorescence reduction assay			17/11/2019	OJCharles			A
250	HCMV	AD169	UL56	L241P						218								Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure	https://aac.asm.org/content/aac/58/1/610.full.pdf	doi.org/10.1128/AAC.01794-13	Recombinant BAC 	GFP fluorescence reduction assay			17/11/2019	OJCharles			A
251	HCMV	AD169	UL56	V236M						45								Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure	https://aac.asm.org/content/aac/58/1/610.full.pdf	doi.org/10.1128/AAC.01794-13	Recombinant BAC 	GFP fluorescence reduction assay			17/11/2019	OJCharles			A
252	HCMV	AD169	UL56	R369G						44								Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure	https://aac.asm.org/content/aac/58/1/610.full.pdf	doi.org/10.1128/AAC.01794-13	Recombinant BAC 	GFP fluorescence reduction assay			17/11/2019	OJCharles			A
253	HCMV	AD169	UL56	R369M						13								Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure	https://aac.asm.org/content/aac/58/1/610.full.pdf	doi.org/10.1128/AAC.01794-13	Recombinant BAC 	GFP fluorescence reduction assay			17/11/2019	OJCharles			A
254	HCMV	AD169	UL56	R369S						48								Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure	https://aac.asm.org/content/aac/58/1/610.full.pdf	doi.org/10.1128/AAC.01794-13	Recombinant BAC 	GFP fluorescence reduction assay			17/11/2019	OJCharles			A
255	HCMV	AD169	UL56	C25F						46								New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir	https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf	doi.org/10.1128/AAC.00922-18	Recombinant BAC 	SEAP	UL56	V231L	17/11/2019	OJCharles		AD169	A
256	HCMV	AD169	UL56	T244K						8.2								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP	UL56	F261L	17/11/2019	OJCharles			A
257	HCMV	AD169	UL56	E237D						104								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP	UL56	T244K; F261L	17/11/2019	OJCharles			A
258	HCMV	AD169	UL56	V236L						260								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP	UL56	L257I	17/11/2019	OJCharles			A
259	HCMV	AD169	UL56	V236M						3000								Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance	https://aac.asm.org/content/aac/59/10/6588.full.pdf	doi.org/10.1128/AAC.01623-15	Recombinant BAC 	SEAP	UL56	L257I; M329T	17/11/2019	OJCharles			A
260	HCMV	AD169	UL56	S229F						54								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP	UL56	L254F; L257I	17/11/2019	OJCharles		AD169	A
265	HCMV	AD169	UL56	E237D						34								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP	UL89	D344E	17/11/2019	OJCharles		AD169	A
266	HCMV	AD169	UL56	F261L						4.8								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP	UL89	D344E	17/11/2019	OJCharles		AD169	A
267	HCMV	AD169	UL56	M329T						8								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP	UL89	D344E	17/11/2019	OJCharles		AD169	A
268	HCMV	AD169	UL56	Q204R						2.5								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP	UL89	D344E	17/11/2019	OJCharles		AD169	A
269	HCMV	AD169	UL51	P91S						2.1								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
270	HCMV	AD169	UL51	P91S						6.3								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP	UL56	S229F	17/11/2019	OJCharles		AD169	A
271	HCMV	AD169	UL51	P91S						28								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP	UL56	V236M	17/11/2019	OJCharles		AD169	A
272	HCMV	AD169	UL51	P91S						126								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP	UL56	R369M	17/11/2019	OJCharles		AD169	A
273	HCMV	AD169	UL51	P91S						4								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP	UL89	D344E	17/11/2019	OJCharles		AD169	A
274	HCMV	AD169	UL97	L337M	1									3.5				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
275	HCMV	AD169	UL97	F342S	7.8									18	17			Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance	https://aac.asm.org/content/aac/57/7/3375.full.pdf	doi.org/10.1128/AAC.00511-13	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
276	HCMV		UL97	V353A	1									14				Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance	https://academic.oup.com/jid/article/196/1/91/844651	doi.org/10.1086/518514	Marker Transfer 	SEAP			17/11/2019	OJCharles		AD169	A
277	HCMV	AD169	UL97	del355	16									304	23			Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance	https://aac.asm.org/content/aac/57/7/3375.full.pdf	doi.org/10.1128/AAC.00511-13	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
278	HCMV	AD169	UL97	V356G	5.5									108	7			Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance	https://aac.asm.org/content/aac/57/7/3375.full.pdf	doi.org/10.1128/AAC.00511-13	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
279	HCMV	AD169	UL97	L397R	1.5									200				Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance	https://academic.oup.com/jid/article-lookup/doi/10.1086/518514	doi.org/10.1086/518514	Marker Transfer 	SEAP			17/11/2019	OJCharles			A
280	HCMV	AD169	UL97	T409M	0.9									81				Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance	https://academic.oup.com/jid/article/196/1/91/844651	doi.org/10.1086/518514	Marker Transfer 	SEAP			17/11/2019	OJCharles		AD169	A
281	HCMV	AD169	UL97	H411L	0.7									69				Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant	https://jvi.asm.org/content/82/1/246.short	doi.org/10.1128/JVI.01787-07	Marker transfer	SEAP			17/11/2019	OJCharles		AD169	A
282	HCMV	AD169	UL97	H411N	1									9				Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant	https://jvi.asm.org/content/82/1/246.short	doi.org/10.1128/JVI.01787-07	Marker transfer	SEAP			17/11/2019	OJCharles		AD169	A
283	HCMV	AD169	UL97	H411Y	0.5									12				Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant	https://jvi.asm.org/content/82/1/246.short	doi.org/10.1128/JVI.01787-07	Marker transfer	SEAP			17/11/2019	OJCharles		AD169	A
284	HCMV	AD169	UL97	D456N	12									278				Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions	https://journals.asm.org/doi/full/10.1128/aac.01726-13	doi.org/10.1128/aac.01726-13	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
285	HCMV	AD169	UL97	V466G	11									321	17			Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance	https://aac.asm.org/content/aac/57/7/3375.full.pdf	doi.org/10.1128/AAC.00511-13	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
286	HCMV	AD169	UL97	C480R	9									243				Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions	https://journals.asm.org/doi/full/10.1128/aac.01726-13	doi.org/10.1128/aac.01726-13	Lab derived mutant 	PRA or SEAP			17/11/2019	OJCharles		AD169	A
287	HCMV	AD169	UL97	P521L	17									445	20			Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance	https://aac.asm.org/content/aac/57/7/3375.full.pdf	doi.org/10.1128/AAC.00511-13	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
288	HCMV	AD169	UL97	del617	10									372	22			Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions	https://journals.asm.org/doi/full/10.1128/aac.01726-13	doi.org/10.1128/aac.01726-13	Lab derived mutant 	PRA or SEAP			17/11/2019	OJCharles		AD169	A
289	HCMV	AD169	UL97	V353A	1									227				Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant	https://jvi.asm.org/content/82/1/246.short	doi.org/10.1128/JVI.01787-07	Marker transfer	SEAP	UL97	H411L	17/11/2019	OJCharles		AD169	A
290	HCMV	AD169	UL97	V353A	0.7									164				Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant	https://jvi.asm.org/content/82/1/246.short	doi.org/10.1128/JVI.01787-07	Marker transfer	SEAP	UL97	H411Y	17/11/2019	OJCharles		AD169	A
291	HCMV	AD169	UL27	E22*										2				Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir	https://aac.asm.org/content/53/1/81	doi.org/10.1128/AAC.01177-08	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
292	HCMV	AD169	UL27	W153R										1.7				Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir	https://aac.asm.org/content/53/1/81	doi.org/10.1128/AAC.01177-08	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
293	HCMV	AD169	UL27	L193F										2.6				Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir	https://aac.asm.org/content/53/1/81	doi.org/10.1128/AAC.01177-08	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
294	HCMV	AD169	UL27	del218										2.5				Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir	https://aac.asm.org/content/53/1/81	doi.org/10.1128/AAC.01177-08	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
295	HCMV	AD169	UL27	R233S										1.8				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP			17/11/2019	OJCharles		AD169	A
296	HCMV	AD169	UL27	A269T										2				Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir	https://aac.asm.org/content/53/1/81	doi.org/10.1128/AAC.01177-08	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
297	HCMV	AD169	UL27	del301-311										3.1				Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir	https://aac.asm.org/content/53/1/81	doi.org/10.1128/AAC.01177-08	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
298	HCMV	Clinical Isolate	UL27	L335P	1.2									23				Resistance of Human Cytomegalovirus to the Benzimidazole l-Ribonucleoside Maribavir Maps to UL27	https://journals.asm.org/doi/full/10.1128/jvi.77.21.11499-11506.2003#T1	doi.org/10.1128/jvi.77.21.11499-11506.2003	Lab derived mutant 	PRA			17/11/2019	OJCharles		Towne	A
299	HCMV	AD169	UL27	V353E										2.1				Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir	https://aac.asm.org/content/53/1/81	doi.org/10.1128/AAC.01177-08	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
300	HCMV	AD169	UL27	W362R										1.9				Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir	https://aac.asm.org/content/53/1/81	doi.org/10.1128/AAC.01177-08	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
301	HCMV	AD169	UL27	W362*										2.2				Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir	https://aac.asm.org/content/53/1/81	doi.org/10.1128/AAC.01177-08	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
302	HCMV	AD169	UL27	L426F										2.2				Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir	https://aac.asm.org/content/53/1/81	doi.org/10.1128/AAC.01177-08	Recombinant BAC 	SEAP			17/11/2019	OJCharles			A
303	HCMV	AD169	UL27	C415*										3.5				Mutations in the Human Cytomegalovirus UL27 Gene That Confer Resistance to Maribavir	https://journals.asm.org/doi/full/10.1128/jvi.78.13.7124-7130.2004	doi.org/10.1128/jvi.78.13.7124-7130.2004	Marker Transfer	PRA	UL27	A406V	17/11/2019	OJCharles		AD169	A
304	HCMV		UL27	R233S										7.2				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Lab derived mutant 	PRA or SEAP	UL97	L337M	17/11/2019	OJCharles			A
305	HCMV		UL27	R233S										27				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Lab derived mutant 	PRA or SEAP	UL97	V353A	17/11/2019	OJCharles		AD169	A
306	HCMV		UL97	C670Y	Resistant													Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches	https://www.tandfonline.com/doi/full/10.1080/09273948.2019.1645188	doi.org/10.1080/09273948.2019.1645188	Isolated strain 				19/11/2019	OJCharles	Anecdotal		O
307	HCMV	AD169	UL97	F342Y	6									4.5				Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection	https://www.sciencedirect.com/science/article/pii/S0166354219304115	doi.org/10.1016/j.antiviral.2019.104616	Recombinant BAC 	SEAP			21/11/2019	OJCharles			A
308	HCMV	AD169	UL97	C592G	3													Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection	https://www.sciencedirect.com/science/article/pii/S0166354219304115	doi.org/10.1016/j.antiviral.2019.104616	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
309	HCMV	AD169	UL97	H411Y										18				Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection	https://www.sciencedirect.com/science/article/pii/S0166354219304115	doi.org/10.1016/j.antiviral.2019.104616	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
310	HCMV	AD169	UL97	T409M										90				Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection	https://www.sciencedirect.com/science/article/pii/S0166354219304115	doi.org/10.1016/j.antiviral.2019.104616	Recombinant BAC 	SEAP			21/11/2019	OJCharles			A
311	HCMV	AD169	UL97	K359E	3.8									1.2				Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection	https://www.sciencedirect.com/science/article/pii/S0166354219304115	doi.org/10.1016/j.antiviral.2019.104616	Recombinant BAC 	SEAP			21/11/2019	OJCharles			A
312	HCMV	AD169	UL97	K359Q	3.7									1.3				Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection	https://www.sciencedirect.com/science/article/pii/S0166354219304115	doi.org/10.1016/j.antiviral.2019.104616	Recombinant BAC 	SEAP			21/11/2019	OJCharles			A
313	HCMV	AD169	UL97	F342Y	5.9									56				Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection	https://www.sciencedirect.com/science/article/pii/S0166354219304115	doi.org/10.1016/j.antiviral.2019.104616	Recombinant BAC 	SEAP	UL97	H411Y	21/11/2019	OJCharles			A
320	HCMV	TB40	UL54	L516W	Resistant		Resistant											Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance	https://www.sciencedirect.com/science/article/abs/pii/S0166354216300870	doi.org/10.1016/j.antiviral.2016.04.002	Recombinant BAC 	PRA or SEAP			21/11/2019	OJCharles		TB40	A
321	HCMV	TB40	UL54	V715A			Polymorphism	Resistant										Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance	https://www.sciencedirect.com/science/article/abs/pii/S0166354216300870	doi.org/10.1016/j.antiviral.2016.04.002	Recombinant BAC 	PRA or SEAP			21/11/2019	OJCharles		TB40	A
341	HCMV	Susceptible Clinical Isolate	UL97	A594V	Resistant													Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.	https://www.ncbi.nlm.nih.gov/pubmed/14739146	doi.org/10.1093/jac/dkh065	Isolated strain 				16/03/2020	OJCharles	Anecdotal		O
342	HCMV	Susceptible Clinical Isolate	UL54	P522S	Resistant		Resistant											Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.	https://www.ncbi.nlm.nih.gov/pubmed/14739146	doi.org/10.1093/jac/dkh065	Isolated strain 				16/03/2020	OJCharles	Anecdotal		O
343	HCMV	AD169	UL56	V236M	1		1.9	1.1		46								Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir	https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract	doi.org/10.1093/infdis/jiv352	Recombinant BAC 	GFP fluorescence reduction assay			16/03/2020	OJCharles			A
344	HCMV	AD169	UL56	D414N	0.4		0.3	0.4		0.9								Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir	https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract	doi.org/10.1093/infdis/jiv352	Recombinant BAC 	GFP fluorescence reduction assay			16/03/2020	OJCharles			A
345	HCMV	AD169	UL56	S227I	0.4		0.3	0.4		0.2								Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir	https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract	doi.org/10.1093/infdis/jiv352	Recombinant BAC 	GFP fluorescence reduction assay			16/03/2020	OJCharles			A
346	HCMV	AD169	UL56	R410G	0.8		0.2	0.4		0.4								Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir	https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract	doi.org/10.1093/infdis/jiv352	Recombinant BAC 	GFP fluorescence reduction assay			16/03/2020	OJCharles			A
347	HCMV		UL56	E237G						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	cannot find key supporting data		O
348	HCMV		UL56	M31I						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
349	HCMV		UL56	M31V						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
350	HCMV		UL56	F41L						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
351	HCMV		UL56	L26P						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
352	HCMV		UL56	I48M						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
353	HCMV		UL56	A103V						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
354	HCMV		UL56	E141*						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
355	HCMV		UL56	N148D						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
356	HCMV		UL56	E157G						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
357	HCMV		UL56	Q182K						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
358	HCMV		UL56	Q213R						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
359	HCMV		UL56	S255L						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
360	HCMV		UL56	S269G						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
361	HCMV		UL56	E276G						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
362	HCMV		UL56	I313V						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
363	HCMV		UL56	C325W						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
364	HCMV		UL56	S378N						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
365	HCMV		UL56	S445N						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
366	HCMV		UL56	E485G						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
367	HCMV		UL56	I535V						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
368	HCMV		UL56	del542						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
369	HCMV		UL56	Y575C						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
370	HCMV		UL56	M641T						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
371	HCMV		UL56	L658S						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
372	HCMV		UL56	Y667H						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
373	HCMV		UL56	S705F						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
374	HCMV		UL56	V706A						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
375	HCMV		UL56	L750P						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
376	HCMV		UL56	Y757H						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
377	HCMV		UL56	T775I						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
378	HCMV		UL56	R816W						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
379	HCMV		UL56	P846L						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
380	HCMV		UL89	K41E						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
381	HCMV		UL89	N74S						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
382	HCMV		UL89	S102F						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
383	HCMV		UL89	F124L						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
384	HCMV		UL89	T132A						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
385	HCMV		UL89	V146I						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
386	HCMV		UL89	P176S						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
387	HCMV		UL89	H243R						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
388	HCMV		UL89	H246R						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
389	HCMV		UL89	D309G						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
390	HCMV		UL89	L323P						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
391	HCMV		UL89	T331A						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
392	HCMV		UL89	S373G						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
393	HCMV		UL89	M406V						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
394	HCMV		UL89	N426D						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
395	HCMV		UL89	L458P						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
396	HCMV		UL89	S521G						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
397	HCMV		UL89	L522P						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
398	HCMV		UL89	A532T						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
399	HCMV		UL89	I572V						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
400	HCMV		UL89	Q625*						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
401	HCMV		UL89	T637A						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
402	HCMV		UL89	V656A						Resistant								In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products	https://www.sciencedirect.com/science/article/pii/S0166354219302128	doi.org/10.1080/14656566.2019.1637418	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
403	HCMV	AD169	UL54	V787A	2.9		1.3	5.25										Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis	https://academic.oup.com/jid/article/220/8/1302/5519111	doi.org/10.1093/infdis/jiz298	Recombinant BAC 	GLuc reporter assay			16/03/2020	OJCharles			A
404	HCMV	AD169	UL54	V787E	8.5		2.9	3.4										Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis	https://academic.oup.com/jid/article/220/8/1302/5519111	doi.org/10.1093/infdis/jiz298	Recombinant BAC 	GLuc reporter assay			21/11/2019	OJCharles			A
405	HCMV	AD169	UL54	V787K	3.2		1.8	9.4										Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis	https://academic.oup.com/jid/article/220/8/1302/5519111	doi.org/10.1093/infdis/jiz298	Recombinant BAC 	GLuc reporter assay			21/11/2019	OJCharles			A
406	HCMV		UL54	L501F			Resistant											Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands	https://academic.oup.com/jac/article/74/8/2370/5489804	doi.org/10.1093/jac/dkz196	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
407	HCMV		UL54	A505T			Resistant											Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands	https://academic.oup.com/jac/article/74/8/2370/5489804	doi.org/10.1093/jac/dkz196	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
408	HCMV		UL97	H469Y	Resistant													Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands	https://academic.oup.com/jac/article/74/8/2370/5489804	doi.org/10.1093/jac/dkz196	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
409	HCMV		UL97	A590V	Resistant													Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands	https://academic.oup.com/jac/article/74/8/2370/5489804	doi.org/10.1093/jac/dkz196	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
410	HCMV		UL54	D1129N	Resistant													Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands	https://academic.oup.com/jac/article/74/8/2370/5489804	doi.org/10.1093/jac/dkz196	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
411	HCMV		UL54	V321I	Resistant													Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands	https://academic.oup.com/jac/article/74/8/2370/5489804	doi.org/10.1093/jac/dkz196	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
412	HCMV		UL97	L609F	Resistant		Resistant											Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands	https://academic.oup.com/jac/article/74/8/2370/5489804	doi.org/10.1093/jac/dkz196	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
413	HCMV		UL54	R1030C	Resistant													Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands	https://academic.oup.com/jac/article/74/8/2370/5489804	doi.org/10.1093/jac/dkz196	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
414	HCMV		UL54	G1031A	Resistant													Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands	https://academic.oup.com/jac/article/74/8/2370/5489804	doi.org/10.1093/jac/dkz196	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
415	HCMV		UL54	L394F	Resistant													Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands	https://academic.oup.com/jac/article/74/8/2370/5489804	doi.org/10.1093/jac/dkz196	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
416	HCMV		UL54	E877K	Resistant													Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands	https://academic.oup.com/jac/article/74/8/2370/5489804	doi.org/10.1093/jac/dkz196	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
417	HCMV		UL97	L609F	Resistant		Resistant											Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands	https://academic.oup.com/jac/article/74/8/2370/5489804	doi.org/10.1093/jac/dkz196	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
418	HCMV		UL54	T892A	Resistant													Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands	https://academic.oup.com/jac/article/74/8/2370/5489804	doi.org/10.1093/jac/dkz196	Isolated strain 				21/11/2019	OJCharles	Anecdotal		O
419	HCMV		UL97	M460I	7.8										12			Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility	https://aac.asm.org/content/55/1/382	doi.org/10.1128/AAC.01259-10	Recombinant BAC 	SEAP			22/11/2019	OJCharles			A
420	HCMV		UL97	M460T	9.3										10			Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility	https://aac.asm.org/content/55/1/382	doi.org/10.1128/AAC.01259-10	Recombinant BAC 	SEAP			22/11/2019	OJCharles			A
421	HCMV		UL97	M460V	8.3										4			Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility	https://aac.asm.org/content/55/1/382	doi.org/10.1128/AAC.01259-10	Recombinant BAC 	SEAP			22/11/2019	OJCharles			A
422	HCMV		UL97	H520Q	7.8										20			Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility	https://aac.asm.org/content/55/1/382	doi.org/10.1128/AAC.01259-10	Recombinant BAC 	SEAP			22/11/2019	OJCharles			A
423	HCMV		UL97	C592G	3										3.3			Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility	https://aac.asm.org/content/55/1/382	doi.org/10.1128/AAC.01259-10	Recombinant BAC 	SEAP			22/11/2019	OJCharles			A
424	HCMV		UL97	A594V	8.6										4.5			Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility	https://aac.asm.org/content/55/1/382	doi.org/10.1128/AAC.01259-10	Recombinant BAC 	SEAP			22/11/2019	OJCharles			A
425	HCMV		UL97	L595S	8.5										1.3			Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility	https://aac.asm.org/content/55/1/382	doi.org/10.1128/AAC.01259-10	Recombinant BAC 	SEAP			22/11/2019	OJCharles			A
426	HCMV		UL97	C603R	8.3										8.4			Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility	https://aac.asm.org/content/55/1/382	doi.org/10.1128/AAC.01259-10	Recombinant BAC 	SEAP			22/11/2019	OJCharles			A
427	HCMV		UL97	C603S	1.9										2.8			Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility	https://aac.asm.org/content/55/1/382	doi.org/10.1128/AAC.01259-10	Recombinant BAC 	SEAP			22/11/2019	OJCharles			A
428	HCMV		UL97	C603W	7.9										4.6			Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility	https://aac.asm.org/content/55/1/382	doi.org/10.1128/AAC.01259-10	Recombinant BAC 	SEAP			22/11/2019	OJCharles			A
429	HCMV	AD169	UL54	D515Y	3.2		2.6											Emergence of letermovir resistance in a lung transplant recipient with ganciclovir?resistant cytomegalovirus infection	https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135	doi.org/10.1111/ajt.15135	Recombinant BAC 	SEAP			22/11/2019	OJCharles			A
430	HCMV	AD169	UL54	L516P	4.4		5.9											Emergence of letermovir resistance in a lung transplant recipient with ganciclovir?resistant cytomegalovirus infection	https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135	doi.org/10.1111/ajt.15135	Recombinant BAC 	SEAP			22/11/2019	OJCharles			A
431	HCMV	AD169	UL54	del981-982	7		3.2	2.7										Emergence of letermovir resistance in a lung transplant recipient with ganciclovir?resistant cytomegalovirus infection	https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135	doi.org/10.1111/ajt.15135	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
432	HCMV		UL54	L415N				Resistant										Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial	https://academic.oup.com/cid/article/68/4/632/5049442	doi.org/10.1093/cid/ciy549	Isolated strain 				22/11/2019	OJCharles	Anecdotal		O
433	HCMV		UL54	S734P				Resistant										Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial	https://academic.oup.com/cid/article/68/4/632/5049442	doi.org/10.1093/cid/ciy549	Isolated strain 				22/11/2019	OJCharles	Anecdotal		O
434	HCMV	AD169	UL54	A543P	4.7		16	0.6										New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir	https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf	doi.org/10.1128/AAC.00922-18	Recombinant BAC 	SEAP			22/11/2019	OJCharles			A
435	HCMV	AD169	UL54	S290R	1.7		1.4	2.3										Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/	doi.org/10.1016/j.antiviral.2016.12.003	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
436	HCMV	AD169	UL54	K426E	1.1		1	1.1										Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/	doi.org/10.1016/j.antiviral.2016.12.003	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
437	HCMV	AD169	UL54	N495K	1.3		1	2.6										Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/	doi.org/10.1016/j.antiviral.2016.12.003	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
438	HCMV	AD169	UL54	N495K	1.7		1.2	3.5										Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/	doi.org/10.1016/j.antiviral.2016.12.003	Recombinant BAC 	SEAP	UL54	Q738R	16/03/2020	OJCharles			A
439	HCMV	AD169	UL54	T552N	1.8		1	2.5										Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/	doi.org/10.1016/j.antiviral.2016.12.003	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
440	HCMV	AD169	UL54	Q783R	1.8		0.9	1.7										Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/	doi.org/10.1016/j.antiviral.2016.12.003	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
441	HCMV	AD169	UL54	V798A	1.5		1.1	1.7										Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/	doi.org/10.1016/j.antiviral.2016.12.003	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
442	HCMV	AD169	UL54	E951D	1.8		1.2	3.9										Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/	doi.org/10.1016/j.antiviral.2016.12.003	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
443	HCMV	TOWNE	UL54	T419M	1			8										Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase	https://www.sciencedirect.com/science/article/pii/S138665320200046X	doi.org/10.1016/S1386-6532(02)00046-X	Drug induced lab mutant 	CMV antigen ELISA 			16/03/2020	OJCharles			A
444	HCMV	TOWNE	UL54	Q578H	2			10										Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase	https://www.sciencedirect.com/science/article/pii/S138665320200046X	doi.org/10.1016/S1386-6532(02)00046-X	Drug induced lab mutant 	CMV antigen ELISA 			16/03/2020	OJCharles			A
445	HCMV	TOWNE	UL54	L773V	2			5										Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase	https://www.sciencedirect.com/science/article/pii/S138665320200046X	doi.org/10.1016/S1386-6532(02)00046-X	Drug induced lab mutant 	CMV antigen ELISA 			16/03/2020	OJCharles			A
446	HCMV	TOWNE	UL97	M460V	10			1										Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase	https://www.sciencedirect.com/science/article/pii/S138665320200046X	doi.org/10.1016/S1386-6532(02)00046-X	Drug induced lab mutant 	CMV antigen ELISA 			16/03/2020	OJCharles			A
448	HCMV		UL97	D68N	Polymorphism													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			16/03/2020	OJCharles	occurs with many other mutations unable to establish its solo phenotype		O
449	HCMV		UL97	Q126L	Polymorphism													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			16/03/2020	OJCharles	occurs with many other mutations unable to establish its solo phenotype		O
450	HCMV		UL97	V244I	Polymorphism													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			16/03/2020	OJCharles	occurs with many other mutations unable to establish its solo phenotype		O
451	HCMV	AD169	UL97	D329H	Polymorphism													Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir	https://academic.oup.com/jid/article/185/2/162/2191141	doi.org/10.1086/338362	Marker Transfer 	PRA			16/03/2020	OJCharles		Towne	A
452	HCMV	AD169	UL97	A427V	1													Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome	https://academic.oup.com/jid/article/194/5/579/2191670	doi.org/10.1086/505882	Lab derived mutant 	PRA			16/03/2020	OJCharles			A
453	HCMV	AD169	UL97	Q449K	Polymorphism													Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance	https://academic.oup.com/jid/article-lookup/doi/10.1086/518514	doi.org/10.1086/518514	Lab derived mutant 	SEAP			16/03/2020	OJCharles		AD169	A
454	HCMV	AD169	UL97	V466M	1.3													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			16/03/2020	OJCharles		AD169	A
455	HCMV	AD169	UL97	H469Y	1.2													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			16/03/2020	OJCharles		AD169	A
456	HCMV	AD169	UL97	A478V	0.8													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			16/03/2020	OJCharles		AD169	A
457	HCMV	AD169	UL97	N510S	1.2													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			16/03/2020	OJCharles		AD169	A
458	HCMV	AD169	UL97	M550I	0.85													Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome	https://academic.oup.com/jid/article/194/5/579/2191670	doi.org/10.1086/505882	Lab derived mutant 	PRA			16/03/2020	OJCharles			A
459	HCMV	AD169	UL97	A582V	0.82													Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome	https://academic.oup.com/jid/article/194/5/579/2191670	doi.org/10.1086/505882	Lab derived mutant 	PRA			16/03/2020	OJCharles			A
460	HCMV	AD169	UL97	H587Y	1		1	0.8										Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168698/	doi.org/10.1128/AAC.49.7.2710-2715.2005	Lab derived mutant 	SEAP			16/03/2020	OJCharles			A
461	HCMV	AD169	UL97	A588V	1.1													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			16/03/2020	OJCharles		AD169	A
462	HCMV		UL97	A591V	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Lab derived mutant 	PRA or SEAP			16/03/2020	OJCharles	unable to find referred mutation		O
463	HCMV	AD169	UL97	N597D	1.4													Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786239/	doi.org/10.1002/jmv.21397	Lab derived mutant 	SEAP			16/03/2020	OJCharles			A
464	HCMV	AD169	UL97	K599R	0.9													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			16/03/2020	OJCharles		AD169	A
465	HCMV	AD169	UL97	L600I	1.4													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			16/03/2020	OJCharles		AD169	A
468	HCMV	AD169	UL97	Y617H	0.84													Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome	https://academic.oup.com/jid/article/194/5/579/2191670	doi.org/10.1086/505882	Lab derived mutant 	PRA			16/03/2020	OJCharles			A
469	HCMV	AD169	UL97	G623S	1.1													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			16/03/2020	OJCharles		AD169	A
471	HCMV	AD169	UL97	T659I	1.3													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			16/03/2020	OJCharles		AD169	A
473	HCMV	AD169	UL97	A674T	0.92													Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome	https://academic.oup.com/jid/article/194/5/579/2191670	doi.org/10.1086/505882	Lab derived mutant 	PRA			16/03/2020	OJCharles			A
474	HCMV	Clinical Isolate	UL97	Q19E	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
475	HCMV	Clinical Isolate	UL97	T95S	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
476	HCMV	Clinical Isolate	UL97	S108N	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
477	HCMV	Clinical Isolate	UL97	R112C	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
478	HCMV	Clinical Isolate	UL97	R137C	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
479	HCMV	Clinical Isolate	UL97	E227D	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
480	HCMV	Clinical Isolate	UL97	A582T	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
481	HCMV		UL54	D515G	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Lab derived mutant 	PRA or SEAP			16/03/2020	OJCharles	Ref never shows this		O
485	HCMV	Clinical Isolate	UL54	A15T	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
486	HCMV	Clinical Isolate	UL54	S24L	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
487	HCMV	Clinical Isolate	UL54	S32P	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
488	HCMV	Clinical Isolate	UL54	V95E	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
489	HCMV	Clinical Isolate	UL54	H142Y	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
490	HCMV	Clinical Isolate	UL54	G143S	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
491	HCMV	Clinical Isolate	UL54	I341T	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
492	HCMV	Clinical Isolate	UL54	N345S	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
493	HCMV	Clinical Isolate	UL54	G347D	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
494	HCMV	Clinical Isolate	UL54	V355A	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
495	HCMV	Clinical Isolate	UL54	S464F	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
496	HCMV	Clinical Isolate	UL54	A626V	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
497	HCMV	Clinical Isolate	UL54	P628L	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
498	HCMV	Clinical Isolate	UL54	G629S	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
499	HCMV	Clinical Isolate	UL54	A631G	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
500	HCMV	Clinical Isolate	UL54	S633F	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
501	HCMV	Clinical Isolate	UL54	M640R	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
502	HCMV	Clinical Isolate	UL54	S655L	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
503	HCMV	Clinical Isolate	UL54	S663N	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
504	HCMV	Clinical Isolate	UL54	F669L	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
505	HCMV	Clinical Isolate	UL54	S676G	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
506	HCMV	Clinical Isolate	UL54	G678S	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
507	HCMV	Clinical Isolate	UL54	del 681-688	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
508	HCMV	Clinical Isolate	UL54	N685S	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
509	HCMV	Clinical Isolate	UL54	A688V	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
510	HCMV	Clinical Isolate	UL54	T691A	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
511	HCMV	Clinical Isolate	UL54	A693T	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
512	HCMV	Clinical Isolate	UL54	S695T	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
513	HCMV	Clinical Isolate	UL54	Q697H	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
514	HCMV	Clinical Isolate	UL54	L737M	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
515	HCMV	Clinical Isolate	UL54	V759M	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
516	HCMV	Clinical Isolate	UL54	Q868R	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
517	HCMV	Clinical Isolate	UL54	D870H	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
518	HCMV	Clinical Isolate	UL54	V873L	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
519	HCMV	Clinical Isolate	UL54	G874R	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
520	HCMV	Clinical Isolate	UL54	S884Insert T	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
521	HCMV	Clinical Isolate	UL54	A885S	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
522	HCMV	Clinical Isolate	UL54	A885T	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
523	HCMV	Clinical Isolate	UL54	P887S	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
524	HCMV	Clinical Isolate	UL54	L890F	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
525	HCMV	Clinical Isolate	UL54	T892I	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
527	HCMV	Clinical Isolate	UL54	N898D	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
528	HCMV	Clinical Isolate	UL54	E899K	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
529	HCMV	Clinical Isolate	UL54	V927M	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
530	HCMV	Clinical Isolate	UL54	V953A	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
531	HCMV	Clinical Isolate	UL54	A1012V	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
532	HCMV	Clinical Isolate	UL54	L1020I	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
533	HCMV	Clinical Isolate	UL54	T1108A	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
534	HCMV	Clinical Isolate	UL54	N1116H	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
535	HCMV	Clinical Isolate	UL54	A1122T	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
536	HCMV	Clinical Isolate	UL54	G1133S	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
537	HCMV	Clinical Isolate	UL54	S1146N	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
538	HCMV	Clinical Isolate	UL54	N1147S	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
539	HCMV	Clinical Isolate	UL54	R1149T	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
540	HCMV	Clinical Isolate	UL54	del1151	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
541	HCMV	Clinical Isolate	UL54	P1153S	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
542	HCMV	Clinical Isolate	UL54	A1154P	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
543	HCMV	Clinical Isolate	UL54	del1156	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
544	HCMV	Clinical Isolate	UL54	P1162L	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
545	HCMV	Clinical Isolate	UL54	S1235T	Polymorphism													Antiviral Drug Resistance of Human Cytomegalovirus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/	doi.org/10.1128/CMR.00009-10	Isolated strain 	Genotyping sensitive clinical isolates			16/03/2020	OJCharles	Anecdotal		O
546	HCMV	Clinical Isolate	UL97	C603W	1.1		0.9	1.5										High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes	https://academic.oup.com/jid/article/176/1/69/901024	doi.org/10.1086/514041	Isolated strain 	PRA			16/03/2020	OJCharles			A
547	HCMV	Clinical Isolate	UL97	H469Y	1.3		1.5	1.9										High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes	https://academic.oup.com/jid/article/176/1/69/901024	doi.org/10.1086/514041	Isolated strain 	PRA			16/03/2020	OJCharles			A
548	HCMV	Clinical Isolate	UL97	C603W	2		0.8	2										High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes	https://academic.oup.com/jid/article/176/1/69/901024	doi.org/10.1086/514041	Isolated strain 	PRA			16/03/2020	OJCharles			A
549	HCMV	AD169	UL54	del413	3.8		5.8	1.3	5.2									Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/	doi.org/10.1128/AAC.00214-16	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
550	HCMV	AD169	UL54	A809V				4.3										Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/	doi.org/10.1128/AAC.00214-16	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
551	HCMV	AD169	UL54	E303G	7.3		20	0.8	11									Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/	doi.org/10.1128/AAC.00214-16	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
552	HCMV	AD169	UL54	E303D	6.3		16	0.8	9.7									Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/	doi.org/10.1128/AAC.00214-16	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
553	HCMV	AD169	UL54	N408K	3.9		21	0.8	11									Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/	doi.org/10.1128/AAC.00214-16	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
554	HCMV	AD169	UL54	D413Y	4.4		9.3	1	6									Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/	doi.org/10.1128/AAC.00214-16	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
555	HCMV	AD169	UL54	V812L	2.1		3.1	2	2.4									Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/	doi.org/10.1128/AAC.00214-16	Recombinant BAC 	SEAP			16/03/2020	OJCharles			A
556	HCMV	AD169	UL54	E303G	10		34	1.4	17									Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/	doi.org/10.1128/AAC.00214-16	Recombinant BAC 	SEAP	UL54	V812L	16/03/2020	OJCharles			A
557	HCMV	AD169	UL56	M3V						1								Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients	https://academic.oup.com/jid/article/221/7/1117/5645458	doi.org/10.1093/infdis/jiz577	Recombinant BAC 	SEAP			14/05/2020	OJCharles			A
558	HCMV	AD169	UL56	V236M						50.2								Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients	https://academic.oup.com/jid/article/221/7/1117/5645458	doi.org/10.1093/infdis/jiz577	Recombinant BAC 	SEAP			14/05/2020	OJCharles			A
559	HCMV	AD169	UL56	E237G	2.1		1.4	1.3		13								Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients	https://academic.oup.com/jid/article/221/7/1117/5645458	doi.org/10.1093/infdis/jiz577	Recombinant BAC 	SEAP			14/05/2020	OJCharles			A
560	HCMV	AD169	UL56	S255L						1.1								Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients	https://academic.oup.com/jid/article/221/7/1117/5645458	doi.org/10.1093/infdis/jiz577	Recombinant BAC 	SEAP			14/05/2020	OJCharles			A
561	HCMV	AD169	UL56	C325W	1.2		1	1.1		8262								Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients	https://academic.oup.com/jid/article/221/7/1117/5645458	doi.org/10.1093/infdis/jiz577	Recombinant BAC 	SEAP			14/05/2020	OJCharles			A
562	HCMV	AD169	UL56	R369T	1.5		1.2	1.1		52								Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients	https://academic.oup.com/jid/article/221/7/1117/5645458	doi.org/10.1093/infdis/jiz577	Recombinant BAC 	SEAP			14/05/2020	OJCharles			A
563	HCMV	AD169	UL56	del445-447						1								Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients	https://academic.oup.com/jid/article/221/7/1117/5645458	doi.org/10.1093/infdis/jiz577	Recombinant BAC 	SEAP	UL56	E485G	14/05/2020	OJCharles			A
564	HCMV	AD169	UL56	E485G						0.9								Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients	https://academic.oup.com/jid/article/221/7/1117/5645458	doi.org/10.1093/infdis/jiz577	Recombinant BAC 	SEAP			14/05/2020	OJCharles			A
565	HCMV	AD169	UL56	Y575C						0.9								Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients	https://academic.oup.com/jid/article/221/7/1117/5645458	doi.org/10.1093/infdis/jiz577	Recombinant BAC 	SEAP			14/05/2020	OJCharles			A
566	HCMV	AD169	UL56	F626S						0.5								Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients	https://academic.oup.com/jid/article/221/7/1117/5645458	doi.org/10.1093/infdis/jiz577	Recombinant BAC 	SEAP			14/05/2020	OJCharles			A
567	HCMV	AD169	UL56	L726V						1								Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients	https://academic.oup.com/jid/article/221/7/1117/5645458	doi.org/10.1093/infdis/jiz577	Recombinant BAC 	SEAP			14/05/2020	OJCharles			A
568	HCMV	AD169	UL56	T775I						1								Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients	https://academic.oup.com/jid/article/221/7/1117/5645458	doi.org/10.1093/infdis/jiz577	Recombinant BAC 	SEAP			14/05/2020	OJCharles			A
569	HCMV	AD169	UL56	del789-791						1								Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients	https://academic.oup.com/jid/article/221/7/1117/5645458	doi.org/10.1093/infdis/jiz577	Recombinant BAC 	SEAP			14/05/2020	OJCharles			A
570	HCMV	AD169	UL56	V814A						1								Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients	https://academic.oup.com/jid/article/221/7/1117/5645458	doi.org/10.1093/infdis/jiz577	Recombinant BAC 	SEAP			14/05/2020	OJCharles			A
571	HCMV	AD169	UL56	R816W						0.9								Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients	https://academic.oup.com/jid/article/221/7/1117/5645458	doi.org/10.1093/infdis/jiz577	Recombinant BAC 	SEAP			14/05/2020	OJCharles			A
572	HCMV	AD169	UL89	I531T						1								Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients	https://academic.oup.com/jid/article/221/7/1117/5645458	doi.org/10.1093/infdis/jiz577	Recombinant BAC 	SEAP			14/05/2020	OJCharles			A
573	HCMV	AD169	UL54	Q579I	0.16			0.06										Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase	https://aac.asm.org/content/aac/64/4/e01910-19.full.pdf	doi.org/10.1128/AAC.01910-19	Recombinant BAC 	GLuc reporter assay			22/07/2020	OJCharles			A
574	HCMV	AD169	UL54	K805Q	1			0.19										Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase	https://aac.asm.org/content/aac/64/4/e01910-19.full.pdf	doi.org/10.1128/AAC.01910-19	Recombinant BAC 	GLuc reporter assay			22/07/2020	OJCharles			A
575	HCMV	AD169	UL54	E756K	12.7		2.9	5.3										Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/	doi.org/10.1128/jcm.02205-14	Recombinant BAC 	GLuc reporter assay	UL54	A594V	23/11/2020	OJCharles			A
576	HCMV	AD169	UL54	V526L	13.2		2.7	1.7										Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/	doi.org/10.1128/jcm.02205-14	Recombinant BAC 	GLuc reporter assay	UL54	A594V	23/11/2020	OJCharles			A
577	HCMV	AD169	UL54	V526L	18.9		3.5	1.9										Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/	doi.org/10.1128/jcm.02205-14	Recombinant BAC 	GLuc reporter assay	UL54	L595F	23/11/2020	OJCharles			A
578	HCMV	AD169	UL54	P744T	0.9		1.1	1.1										Cyclopropavir Susceptibility of Cytomegalovirus DNA Polymerase Mutants Selected after Antiviral Drug Exposure	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256009/	doi.org/10.1128/AAC.05559-11	Lab derived mutant 	PRA or SEAP			23/11/2020	OJCharles			A
579	HCMV	AD169	UL54	W780V	1.5			1.9										Contrasting Effects of W781V and W780V Mutations in Helix N of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Antiviral Drug Susceptibility	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442382/	doi.org/10.1128/JVI.03360-14	Marker Transfer 	PRA			24/11/2020	OJCharles			A
1655	HCMV	AD169	UL97	C592G	3.1													Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1656	HCMV	AD169	UL97	F342Y	5.9									4.2				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1657	HCMV	AD169	UL97	Y335H	0.9									1				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1658	HCMV	AD169	UL97	V345I	1.3									0.4				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1659	HCMV	AD169	UL97	L348V	0.9									1.6				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1660	HCMV	AD169	UL97	K359N	2.1									0.7				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1661	HCMV	AD169	UL97	E362D	3.8									0.1				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1662	HCMV	AD169	UL97	A378T	1									1.1				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1663	HCMV	AD169	UL97	V388M	1.2									1.1				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1664	HCMV	AD169	UL97	H415Y	1.1									0.6				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1665	HCMV	AD169	UL97	A435V	1									0.6				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1666	HCMV	AD169	UL97	C437Y	0.9									0.9				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1667	HCMV	AD169	UL54	D301N		0.2	14											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1668	HCMV	AD169	UL54	N408D		0.2	3.3											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1669	HCMV	AD169	UL54	N408K		0.1	32											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1670	HCMV	AD169	UL54	N410K		0.7	2.5											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1671	HCMV	AD169	UL54	F412C		0.2	17											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1672	HCMV	AD169	UL54	F412L		0.2	12											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1673	HCMV	AD169	UL54	K513R		3.6	14											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1674	HCMV	AD169	UL54	D515Y		0.6	2.2											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1675	HCMV	AD169	UL54	L516P		0.2	5.3											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1676	HCMV	AD169	UL54	P522S		0.2	4.4											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1677	HCMV	AD169	UL54	L545W		0.3	6.4											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1678	HCMV	AD169	UL54	Q578H		8.6	2.9	Resistant										Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1679	HCMV	AD169	UL54	T700A		4.6	1.7	Resistant										Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1680	HCMV	AD169	UL54	A809V		5.2	2	Resistant										Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1681	HCMV	AD169	UL54	D981del2		0.8	3.3	Resistant										Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1682	HCMV	AD169	UL54	A987G		0.4	7.7											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1683	HCMV	AD169	UL54	A987V		1.6	0.9	Resistant										Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1701	HCMV	AD169	UL54	I580K	2.1			1.1										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	GLuc reporter assay			22/12/2021	OJCharles		AD169	A
1702	HCMV	AD169	UL54	T584A	1			1										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	GLuc reporter assay			22/12/2021	OJCharles		AD169	A
1703	HCMV	AD169	UL54	L586I	0.6			1										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	GLuc reporter assay			22/12/2021	OJCharles		AD169	A
1704	HCMV	AD169	UL54	V694Q	0.5			1.6										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	GLuc reporter assay			22/12/2021	OJCharles		AD169	A
1705	HCMV	AD169	UL54	Q697P	0.7			3.8										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	GLuc reporter assay			22/12/2021	OJCharles		AD169	A
1706	HCMV	AD169	UL54	A719T	2.4			2.5										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	GLuc reporter assay			22/12/2021	OJCharles		AD169	A
1724	HCMV	Toledo	UL54	T700A	0.9		0.7	7.6										Analysis of Novel Drug-Resistant Human Cytomegalovirus DNA Polymerase Mutations Reveals the Role of a DNA-Binding Loop in Phosphonoformic Acid Resistance	https://www.frontiersin.org/articles/10.3389/fmicb.2022.771978/full	doi.org/10.3389/fmicb.2022.771978	Recombinant BAC 	PRA			04/03/2022	OJCharles		Toledo	A
1725	HCMV	Toledo	UL54	H600L	11.1		4.9	5.2										Analysis of Novel Drug-Resistant Human Cytomegalovirus DNA Polymerase Mutations Reveals the Role of a DNA-Binding Loop in Phosphonoformic Acid Resistance	https://www.frontiersin.org/articles/10.3389/fmicb.2022.771978/full	doi.org/10.3389/fmicb.2022.771978	Recombinant BAC 	PRA			04/03/2022	OJCharles		Toledo	A
1726	HCMV	Toledo	UL54	E756G	1		1.8	8.8										Analysis of Novel Drug-Resistant Human Cytomegalovirus DNA Polymerase Mutations Reveals the Role of a DNA-Binding Loop in Phosphonoformic Acid Resistance	https://www.frontiersin.org/articles/10.3389/fmicb.2022.771978/full	doi.org/10.3389/fmicb.2022.771978	Recombinant BAC 	PRA			04/03/2022	OJCharles		Toledo	A
1727	HCMV	Toledo	UL54	H600L	1.4		0.7	37										Analysis of Novel Drug-Resistant Human Cytomegalovirus DNA Polymerase Mutations Reveals the Role of a DNA-Binding Loop in Phosphonoformic Acid Resistance	https://www.frontiersin.org/articles/10.3389/fmicb.2022.771978/full	doi.org/10.3389/fmicb.2022.771978	Recombinant BAC 	PRA	UL54	T700A	04/03/2022	OJCharles		Toledo	A
1730	HCMV	AD169	UL97	C480F	17.5			0.84						10				Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients	https://academic.oup.com/jid/article/224/6/1024/6105173	doi.org/10.1093/infdis/jiab029	Recombinant BAC 	GFP fluorescence reduction assay			05/08/2023	OJCharles		AD169	A
1733	HCMV	AD169	UL56	R246C	0.6		1.8	0.9		0.8				0.5				Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045154/	doi.org/10.1128/spectrum.00191-22	Recombinant BAC 	GFP fluorescence reduction assay			09/10/2022	OJCharles		AD169	A
1734	HCMV	AD169	UL51	D12E						1.4								First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure	https://www.sciencedirect.com/science/article/pii/S0166354222001309	doi.org/10.1016/j.antiviral.2022.105361	Recombinant BAC 	GFP fluorescence reduction assay			09/10/2022	OJCharles		AD169	A
1735	HCMV	AD169	UL51	A95V						13.8								First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure	https://www.sciencedirect.com/science/article/pii/S0166354222001309	doi.org/10.1016/j.antiviral.2022.105361	Recombinant BAC 	GFP fluorescence reduction assay			09/10/2022	OJCharles		AD169	A
1736	HCMV	AD169	UL51	V113L						1.5								First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure	https://www.sciencedirect.com/science/article/pii/S0166354222001309	doi.org/10.1016/j.antiviral.2022.105361	Recombinant BAC 	GFP fluorescence reduction assay			09/10/2022	OJCharles		AD169	A
1737	HCMV	AD169	UL51	A95V						128								First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure	https://www.sciencedirect.com/science/article/pii/S0166354222001309	doi.org/10.1016/j.antiviral.2022.105361	Recombinant BAC 	GFP fluorescence reduction assay	UL56	L257I	09/10/2022	OJCharles		AD169	A
1738	HCMV	AD169	UL56	V231L						8.8								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1739	HCMV	AD169	UL56	Q234R						2								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1740	HCMV	AD169	UL56	L243P						1								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1741	HCMV	AD169	UL56	S262C						1								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1742	HCMV	AD169	UL56	L328I						1.4								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1743	HCMV	AD169	UL56	H335Y						0.8								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1744	HCMV	AD169	UL56	E339G						1.2								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1745	HCMV	AD169	UL56	K350R						1								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1746	HCMV	AD169	UL56	V363I						3.7								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1747	HCMV	AD169	UL56	N368I						1.3								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1748	HCMV	AD169	UL56	R369K						4.9								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1749	HCMV	AD169	UL56	T399I						0.8								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1750	HCMV	AD169	UL54	G441S	Polymorphism		Polymorphism	Polymorphism										Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection	https://academic.oup.com/jid/article-abstract/226/9/1528/6672993	doi.org/10.1093/infdis/jiac349	Isolated strain 	PRA			05/08/2023	OJCharles		AD169	A
1751	HCMV	AD169	UL54	A543V			Resistant											Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection	https://academic.oup.com/jid/article-abstract/226/9/1528/6672993	doi.org/10.1093/infdis/jiac349	Isolated strain 	PRA	UL54	M460I	05/08/2023	OJCharles	co-occurs with M460I which causes GCVr and has not been tested against CDV but given GCVr it is more likely it causes CDVr and A543V is therefore hard to determine	AD169	O
1752	HCMV	AD169	UL54	F460S	Polymorphism		Polymorphism	Polymorphism										Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection	https://academic.oup.com/jid/article-abstract/226/9/1528/6672993	doi.org/10.1093/infdis/jiac349	Isolated strain 	PRA			05/08/2023	OJCharles		AD169	A
1753	HCMV	AD169	UL54	R512C	Polymorphism		Polymorphism	Polymorphism										Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection	https://academic.oup.com/jid/article-abstract/226/9/1528/6672993	doi.org/10.1093/infdis/jiac349	Isolated strain 	PRA			05/08/2023	OJCharles		AD169	A
1754	HCMV	AD169	UL54	A928T	Resistant		Resistant	Resistant										Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection	https://academic.oup.com/jid/article-abstract/226/9/1528/6672993	doi.org/10.1093/infdis/jiac349	Isolated strain 	PRA			05/08/2023	OJCharles	no other mutations noted	AD169	A
1755	HCMV	AD169	UL56	F345L	1.42		1.67	1		1								Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection	https://academic.oup.com/jid/article-abstract/226/9/1528/6672993	doi.org/10.1093/infdis/jiac349	Isolated strain 	PRA			05/08/2023	OJCharles		AD169	A
1756	HCMV	AD169	UL56	P800L	0.23		0.13	1		1.1								Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection	https://academic.oup.com/jid/article-abstract/226/9/1528/6672993	doi.org/10.1093/infdis/jiac349	Isolated strain 	PRA			05/08/2023	OJCharles		AD169	A
1760	HCMV	AD169	UL56	V231L						5.6								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1761	HCMV	AD169	UL56	L241P						173								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1762	HCMV	AD169	UL56	R369M						16								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1763	HCMV	AD169	UL89	D344E						1.6								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1764	HCMV	AD169	UL56	V231L						8.1								New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir	https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf	doi.org/10.1128/AAC.00922-18	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1765	HCMV	AD169	UL56	V236M						49								New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir	https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf	doi.org/10.1128/AAC.00922-18	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1766	HCMV	AD169	UL56	L257F						14								New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir	https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf	doi.org/10.1128/AAC.00922-18	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1767	HCMV	AD169	UL56	C325Y						8800								New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir	https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf	doi.org/10.1128/AAC.00922-18	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1768	HCMV	AD169	UL27	R448P										1.5				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1769	HCMV	AD169	UL27	D534Y										1.4				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1770	HCMV	AD169	UL97	I324V										0.6				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1771	HCMV	AD169	UL97	S334G										1.1				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1772	HCMV	AD169	UL27	R233S										2				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP	UL97	S334G	07/08/2023	OJCharles		AD169	A
1773	HCMV	AD169	UL97	L337M										7.2				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP	UL27	R233S	07/08/2023	OJCharles		AD169	A
1774	HCMV	AD169	UL97	V353A										12				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1775	HCMV	AD169	UL97	S386L										0.9				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1776	HCMV	Clinical isolate	UL97	M460V	6									1				Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action	https://journals.asm.org/doi/full/10.1128/aac.46.8.2365-2372.2002	doi.org/10.1128/aac.46.8.2365-2372.2002	Isolated strain 	PCR DNA hybridization assay			07/08/2023	OJCharles		AD169	A
1777	HCMV	Clinical isolate	UL97	H520E	5.2									1.6				Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action	https://journals.asm.org/doi/full/10.1128/aac.46.8.2365-2372.2002	doi.org/10.1128/aac.46.8.2365-2372.2002	Isolated strain 	PCR DNA hybridization assay			07/08/2023	OJCharles		AD169	A
1778	HCMV	Clinical isolate	UL97	A594V	6													Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action	https://journals.asm.org/doi/full/10.1128/aac.46.8.2365-2372.2002	doi.org/10.1128/aac.46.8.2365-2372.2002	Isolated strain 	PCR DNA hybridization assay			07/08/2023	OJCharles		AD169	A
1779	HCMV	Clinical isolate	UL54	T700A	2.2									0.8				Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action	https://journals.asm.org/doi/full/10.1128/aac.46.8.2365-2372.2002	doi.org/10.1128/aac.46.8.2365-2372.2002	Isolated strain 	PCR DNA hybridization assay			07/08/2023	OJCharles		AD169	A
1780	HCMV	Clinical isolate	UL97	L397R	1									34				Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action	https://journals.asm.org/doi/full/10.1128/aac.46.8.2365-2372.2002	doi.org/10.1128/aac.46.8.2365-2372.2002	Isolated strain 	PCR DNA hybridization assay			07/08/2023	OJCharles		AD169	A
1781	HCMV	AD169	UL27	V353A										16				Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir	https://aac.asm.org/content/53/1/81	doi.org/10.1128/AAC.01177-08	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1782	HCMV	AD169	UL97	V353A	1.7									15				Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant	https://jvi.asm.org/content/82/1/246.short	doi.org/10.1128/JVI.01787-07	Marker transfer	SEAP			07/08/2023	OJCharles		AD169	A
1783	HCMV	AD169	UL97	H587Y	1									1				Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant	https://jvi.asm.org/content/82/1/246.short	doi.org/10.1128/JVI.01787-07	Marker transfer	SEAP			07/08/2023	OJCharles		AD169	A
1784	HCMV	AD169	UL27	R233S										4.7				Mutations in the Human Cytomegalovirus UL27 Gene That Confer Resistance to Maribavir	https://journals.asm.org/doi/full/10.1128/jvi.78.13.7124-7130.2004	doi.org/10.1128/jvi.78.13.7124-7130.2004	Marker Transfer	PRA			07/08/2023	OJCharles		AD169	A
1785	HCMV	AD169	UL27	W362R										2				Mutations in the Human Cytomegalovirus UL27 Gene That Confer Resistance to Maribavir	https://journals.asm.org/doi/full/10.1128/jvi.78.13.7124-7130.2004	doi.org/10.1128/jvi.78.13.7124-7130.2004	Marker Transfer	PRA			07/08/2023	OJCharles		AD169	A
1786	HCMV	AD169	UL97	M460V	7									0.3				Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance	https://academic.oup.com/jid/article-lookup/doi/10.1086/518514	doi.org/10.1086/518514	Marker Transfer 	SEAP			07/08/2023	OJCharles		AD169	A
1787	HCMV	AD169	UL97	V353A										10				Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance	https://aac.asm.org/content/aac/57/7/3375.full.pdf	doi.org/10.1128/AAC.00511-13	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1788	HCMV	AD169	UL97	M460I											11			Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance	https://aac.asm.org/content/aac/57/7/3375.full.pdf	doi.org/10.1128/AAC.00511-13	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1789	HCMV	AD169	UL97	C592G	2.7													Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance	https://aac.asm.org/content/aac/57/7/3375.full.pdf	doi.org/10.1128/AAC.00511-13	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1790	HCMV	AD169	UL97	A594V	8.3													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1791	HCMV	AD169	UL97	C603R	8.3													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1792	HCMV	AD169	UL97	V665I	1.1													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1793	HCMV	AD169	UL97	K355M	25										13			Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions	https://journals.asm.org/doi/full/10.1128/aac.01726-13	doi.org/10.1128/aac.01726-13	Recombinant BAC 	PRA			07/08/2023	OJCharles		AD169	A
1794	HCMV	Towne	UL97	C592G	2.5													Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir	https://academic.oup.com/jid/article/185/2/162/2191141	doi.org/10.1086/338362	Marker Transfer 	PRA			07/08/2023	OJCharles		Towne	A
1795	HCMV	Towne	UL97	L634Q	1.1													Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir	https://academic.oup.com/jid/article/185/2/162/2191141	doi.org/10.1086/338362	Marker Transfer 	PRA			07/08/2023	OJCharles		Towne	A
1796	HCMV	Towne	UL97	C607F	1.6													Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir	https://academic.oup.com/jid/article/185/2/162/2191141	doi.org/10.1086/338362	Marker Transfer 	PRA			07/08/2023	OJCharles		Towne	A
1797	HCMV	AD169	UL97	L595S	4.9													Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir	https://academic.oup.com/jid/article/185/2/162/2191141	doi.org/10.1086/338362	Marker Transfer 	PRA			07/08/2023	OJCharles		AD169	A
1798	HCMV	AD169	UL97	C592G	2.6													Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir	https://academic.oup.com/jid/article/185/2/162/2191141	doi.org/10.1086/338362	Marker Transfer 	PRA			07/08/2023	OJCharles		AD169	A
1799	HCMV	Clinical Isolate	UL97	L595F	1		0.4	1.5										High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes	https://academic.oup.com/jid/article/176/1/69/901024	doi.org/10.1086/514041	Isolated strain 	PRA			07/08/2023	OJCharles			A
1800	HCMV	Clinical Isolate	UL97	A594V	1.7		1.7	1.1										High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes	https://academic.oup.com/jid/article/176/1/69/901024	doi.org/10.1086/514041	Isolated strain 	PRA			07/08/2023	OJCharles			A
1801	HCMV	Clinical Isolate	UL97	M460V	1.7		1.2	0.9										High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes	https://academic.oup.com/jid/article/176/1/69/901024	doi.org/10.1086/514041	Isolated strain 	PRA			07/08/2023	OJCharles			A
1802	HCMV	Clinical Isolate	UL97	M460I	2.2		1	0.6										High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes	https://academic.oup.com/jid/article/176/1/69/901024	doi.org/10.1086/514041	Isolated strain 	PRA			07/08/2023	OJCharles			A
1803	HCMV	Clinical Isolate	UL97	L595S	4		1	1										Analysis and Characterization of Antiviral Drugâ€“Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients	https://academic.oup.com/jid/article/186/6/760/2191110	doi.org/10.1086/342844	Isolated strain 	PRA			07/08/2023	OJCharles			A
1804	HCMV	Clinical Isolate	UL97	H520Q	3.2		0.5	1.5										Analysis and Characterization of Antiviral Drugâ€“Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients	https://academic.oup.com/jid/article/186/6/760/2191110	doi.org/10.1086/342844	Isolated strain 	PRA			07/08/2023	OJCharles			A
1805	HCMV	Clinical Isolate	UL97	A594P	2.6		2.5	0.7										Analysis and Characterization of Antiviral Drugâ€“Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients	https://academic.oup.com/jid/article/186/6/760/2191110	doi.org/10.1086/342844	Isolated strain 	PRA			07/08/2023	OJCharles			A
1806	HCMV	Clinical Isolate	UL54	F412S	2.3		16	1										Analysis and Characterization of Antiviral Drugâ€“Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients	https://academic.oup.com/jid/article/186/6/760/2191110	doi.org/10.1086/342844	Isolated strain 	PRA			07/08/2023	OJCharles			A
1807	HCMV	Clinical Isolate	UL97	A594V	1.8													Analysis and Characterization of Antiviral Drugâ€“Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients	https://academic.oup.com/jid/article/186/6/760/2191110	doi.org/10.1086/342844	Isolated strain 	PRA			07/08/2023	OJCharles	large discrepencies between reps		O
1808	HCMV	Clinical Isolate	UL97	C607Y	4													Analysis and Characterization of Antiviral Drugâ€“Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients	https://academic.oup.com/jid/article/186/6/760/2191110	doi.org/10.1086/342844	Isolated strain 	PRA			07/08/2023	OJCharles			A
1809	HCMV		UL97	L595F	7													Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma	https://www.jci.org/articles/view/117648	doi.org/10.1172/jci117648	Isolated strain 	PRA			14/08/2023	OJCharles			A
1810	HCMV		UL97	T659I	4													Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma	https://www.jci.org/articles/view/117648	doi.org/10.1172/jci117648	Isolated strain 	PRA			14/08/2023	OJCharles			A
1811	HCMV		UL54	V715M	1			5.5										Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS	https://journals.asm.org/doi/10.1128/JVI.70.3.1390-1395.1996	doi.org/10.1128/jvi.70.3.1390-1395.1996	Marker Transfer	PRA			14/08/2023	OJCharles		AD169	A
1812	HCMV	AD169	UL54	N495K	1		2.5	5.6										Rapid determination of antiviral drug susceptibility of human cytomegalovirus by real-time PCR	https://www.sciencedirect.com/science/article/pii/S0166354208004221	doi.org/10.1016/j.antiviral.2008.09.009	Marker Transfer	PRA			14/08/2023	OJCharles		AD169	A
1813	HCMV	AD169	UL54	L545S	8		10											Rapid determination of antiviral drug susceptibility of human cytomegalovirus by real-time PCR	https://www.sciencedirect.com/science/article/pii/S0166354208004221	doi.org/10.1016/j.antiviral.2008.09.009	Marker Transfer	PRA			14/08/2023	OJCharles		AD169	A
1814	HCMV		UL97	A594V	10													Antiviral Susceptibilities and Analysis of UL97 and DNA Polymerase Sequences of Clinical Cytomegalovirus Isolates from Immunocompromised Patients	https://academic.oup.com/jid/article/175/5/1087/853432	doi.org/10.1086/516446	Isolated strain 	PRA			14/08/2023	OJCharles			A
1815	HCMV		UL97	A594T	5													Antiviral Susceptibilities and Analysis of UL97 and DNA Polymerase Sequences of Clinical Cytomegalovirus Isolates from Immunocompromised Patients	https://academic.oup.com/jid/article/175/5/1087/853432	doi.org/10.1086/516446	Isolated strain 	PRA			14/08/2023	OJCharles			A
1816	HCMV		UL97	C603W	Resistant		Polymorphism	Polymorphism										Drug-resistant cytomegalovirus in transplant recipients: a French cohort study	https://academic.oup.com/jac/article/65/12/2628/755060#13268428	doi.org/10.1093/jac/dkq368	Isolated strain 	PCR DNA hybridization assa			14/08/2023	OJCharles		AD169	A
1817	HCMV		UL54	A834P	Resistant		Resistant	Resistant										Drug-resistant cytomegalovirus in transplant recipients: a French cohort study	https://academic.oup.com/jac/article/65/12/2628/755060#13268428	doi.org/10.1093/jac/dkq368	Isolated strain 	PCR DNA hybridization assa			14/08/2023	OJCharles		AD169	A
1818	HCMV		UL97	M460V	8.2													Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients	www.sciencedirect.com/science/article/pii/S1386653206004161	doi.org/10.1016/j.jcv.2006.11.005	Marker Transfer	SEAP			14/08/2023	OJCharles		AD169	A
1819	HCMV		UL54	D413A	6.5		10	0.8										Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients	www.sciencedirect.com/science/article/pii/S1386653206004161	doi.org/10.1016/j.jcv.2006.11.005	Marker Transfer	SEAP			14/08/2023	OJCharles		AD169	A
1820	HCMV	Towne	UL54	D588N	3.8		2.7	3.2										How Evolution of Mutations Conferring Drug Resistance Affects Viral Dynamics and Clinical Outcomes of Cytomegalovirus-Infected Hematopoietic Cell Transplant Recipients	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC540138/	doi.org/10.1128/JCM.43.1.208-213.2005	Marker Transfer 	PRA			14/08/2023	OJCharles		Towne	A
1821	HCMV		UL97	C592F	4	0.8	1.8	1.6										Aciclovir Selects for Ganciclovir-Cross-Resistance ofHuman Cytomegalovirus In Vitro That is Only in PartExplained by Known Mutations in the UL97 Protein	https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.2003	doi.org/10.1002/jmv.2003	Lab derived mutant 	PRA			14/08/2023	OJCharles			A
1822	HCMV		UL97	K599M	1.5	1.6	1	3.8										Aciclovir Selects for Ganciclovir-Cross-Resistance ofHuman Cytomegalovirus In Vitro That is Only in PartExplained by Known Mutations in the UL97 Protein	https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.2003	doi.org/10.1002/jmv.2003	Lab derived mutant 	PRA			14/08/2023	OJCharles	Reported as L599M compared to AD169 which has K599 and L600. Assuming the correct mutation is K599M		A
1823	HCMV		UL54	F412C	3.6		10	2.5										Evolution of Mutations Conferring Multidrug Resistance during Prophylaxis and Therapy for Cytomegalovirus Disease	https://academic.oup.com/jid/article/176/3/786/872103	doi.org/10.1086/517302	Lab derived mutant 	PRA			14/08/2023	OJCharles		AD169	A
1824	HCMV		UL54	L802M	3.6		1.8	11										Evolution of Mutations Conferring Multidrug Resistance during Prophylaxis and Therapy for Cytomegalovirus Disease	https://academic.oup.com/jid/article/176/3/786/872103	doi.org/10.1086/517302	Lab derived mutant 	PRA			14/08/2023	OJCharles		AD169	A
1825	HCMV	AD169	UL97	D605E	0.6													GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E	https://www.sciencedirect.com/science/article/pii/S0166354201002029	doi.org/10.1016/S0166-3542(01)00202-9	Marker Transfer	PRA			14/08/2023	OJCharles		AD169	A
1826	HCMV	AD169	UL97	A594P	4.6													GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E	https://www.sciencedirect.com/science/article/pii/S0166354201002029	doi.org/10.1016/S0166-3542(01)00202-9	Marker Transfer	PRA			14/08/2023	OJCharles		AD169	A
1827	HCMV	AD169	UL97	A594P	3.8													GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E	https://www.sciencedirect.com/science/article/pii/S0166354201002029	doi.org/10.1016/S0166-3542(01)00202-9	Marker Transfer	PRA	UL97	D605E	14/08/2023	OJCharles		AD169	A
1828	HCMV	TB40	UL97	M460V	5.9													Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay	https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759	doi.org/10.1016/j.jcv.2015.06.090	Recombinant BAC	PRA			14/08/2023	OJCharles		TB40	A
1829	HCMV	TB40	UL97	I610T	2.6													Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay	https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759	doi.org/10.1016/j.jcv.2015.06.090	Recombinant BAC	PRA			14/08/2023	OJCharles		TB40	A
1830	HCMV	TB40	UL97	E596D	1.3													Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay	https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759	doi.org/10.1016/j.jcv.2015.06.090	Recombinant BAC	PRA			14/08/2023	OJCharles		TB40	A
1831	HCMV	TB40	UL54	D515E	2.4		1.6	1.1										Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay	https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759	doi.org/10.1016/j.jcv.2015.06.090	Recombinant BAC	PRA			14/08/2023	OJCharles		TB40	A
1832	HCMV	TB40	UL54	I521T	2.1		4.9	1										Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay	https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759	doi.org/10.1016/j.jcv.2015.06.090	Recombinant BAC	PRA			14/08/2023	OJCharles		TB40	A
1833	HCMV	TB40	UL54	L516M	1.3		1.1	1.2										Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation	https://www.sciencedirect.com/science/article/abs/pii/S0166354213002866	doi.org/10.1016/j.antiviral.2013.09.026	Recombinant BAC	PRA			14/08/2023	OJCharles		TB40	A
1834	HCMV	Clinical isolate	UL97	M460V	15.5													Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation	https://www.sciencedirect.com/science/article/abs/pii/S0166354213002866	doi.org/10.1016/j.antiviral.2013.09.026	Isolated strain	PRA			14/08/2023	OJCharles		TB40	A
1835	HCMV	Clinical isolate	UL97	M615V	1.1													Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis	https://www.sciencedirect.com/science/article/abs/pii/S1386653210000181	doi.org/10.1016/j.jcv.2010.01.009	Recombinant BAC 	PRA			14/08/2023	OJCharles			A
1836	HCMV		UL97	C603R	3.6													Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis	https://www.sciencedirect.com/science/article/abs/pii/S1386653210000181	doi.org/10.1016/j.jcv.2010.01.009	Recombinant BAC 	PRA			14/08/2023	OJCharles			A
1837	HCMV	AD169	UL97	C592G	3													Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene	https://journals.asm.org/doi/10.1128/JCM.00391-17	doi.org/10.1128/jcm.00391-17	Recombinant BAC 	SEAP			14/08/2023	OJCharles		AD169	A
1838	HCMV	AD169	UL97	A594V	6.5													Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene	https://journals.asm.org/doi/10.1128/JCM.00391-17	doi.org/10.1128/jcm.00391-17	Recombinant BAC 	SEAP			14/08/2023	OJCharles		AD169	A
1839	HCMV	AD169	UL97	A591V	3.8													Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene	https://journals.asm.org/doi/10.1128/JCM.00391-17	doi.org/10.1128/jcm.00391-17	Recombinant BAC 	SEAP			14/08/2023	OJCharles		AD169	A
1840	HCMV	AD169	UL97	K599E	1.2													Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene	https://journals.asm.org/doi/10.1128/JCM.00391-17	doi.org/10.1128/jcm.00391-17	Recombinant BAC 	SEAP			14/08/2023	OJCharles		AD169	A
1841	HCMV	AD169	UL97	T601M	1													Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene	https://journals.asm.org/doi/10.1128/JCM.00391-17	doi.org/10.1128/jcm.00391-17	Recombinant BAC 	SEAP			14/08/2023	OJCharles		AD169	A
1842	HCMV	AD169	UL54	L897S	1		1	0.9										Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168698/	doi.org/10.1128/AAC.49.7.2710-2715.2005	Lab derived mutant 	SEAP			15/08/2023	OJCharles	you can draw this as we know UL97H587Y has no impact		A
1843	HCMV	AD169	UL97	M460V	9													Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168698/	doi.org/10.1128/AAC.49.7.2710-2715.2005	Lab derived mutant 	SEAP			15/08/2023	OJCharles			A
1844	HCMV	AD169	UL97	C592G	3		1.4	1										Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168698/	doi.org/10.1128/AAC.49.7.2710-2715.2005	Lab derived mutant 	SEAP			15/08/2023	OJCharles			A
1845	HCMV	AD169	UL97	A594V	9													Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168698/	doi.org/10.1128/AAC.49.7.2710-2715.2005	Lab derived mutant 	SEAP			15/08/2023	OJCharles			A
1846	HCMV	AD169	UL54	N408H	2		3.3	1.1										Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles			A
1847	HCMV	AD169	UL54	L501F	2.6		3.8	1.3										Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles		AD169	A
1848	HCMV	AD169	UL54	T503A	3.1		3.7	1.5										Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles		AD169	A
1849	HCMV	AD169	UL54	K513Q	6.6		18	1										Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles		AD169	A
1850	HCMV	AD169	UL54	P522T	2.1		2	1.4										Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles		AD169	A
1851	HCMV	AD169	UL54	L545F	4		11	1.2										Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles		AD169	A
1852	HCMV	AD169	UL54	C590F	1.6		1.6	2.3										Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles		AD169	A
1853	HCMV	AD169	UL97	A594P	8.1													Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles		AD169	A
1854	HCMV	AD169	UL97	E596Q	2.7													Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles		AD169	A
1940	HCMV	AD169	UL54	V715M	1.2			3.7										Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases 	https://www.sciencedirect.com/science/article/abs/pii/S016635422100036X	doi.org/10.1016/j.antiviral.2021.105046	Recombinant BAC 	PRA			01/12/2023	OJCharles		AD169	A
1941	HCMV	AD169	UL54	V715S	2.9			2.8										Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases 	https://www.sciencedirect.com/science/article/abs/pii/S016635422100036X	doi.org/10.1016/j.antiviral.2021.105046	Recombinant BAC 	PRA			01/12/2023	OJCharles		AD169	A
1952	HCMV	AD169	UL56	V231L						8.1								Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation	https://www.sciencedirect.com/science/article/abs/pii/S016635422400144X	doi.org/10.1016/j.antiviral.2024.105935	Recombinant BAC 	SEAP			31/10/2024	OJCharles		AD169	A
1953	HCMV	AD169	UL56	S229Y						2								Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation	https://www.sciencedirect.com/science/article/abs/pii/S016635422400144X	doi.org/10.1016/j.antiviral.2024.105935	Recombinant BAC 	SEAP			31/10/2024	OJCharles		AD169	A
1954	HCMV	AD169	UL56	M329I						0.77								Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation	https://www.sciencedirect.com/science/article/abs/pii/S016635422400144X	doi.org/10.1016/j.antiviral.2024.105935	Recombinant BAC 	SEAP			31/10/2024	OJCharles		AD169	A
1955	HCMV	AD169	UL97	G343A	8.5									126				Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiae469/7762822	doi.org/10.1093/infdis/jiae469	Recombinant BAC 	SEAP			31/10/2024	OJCharles		AD169	A
1956	HCMV	AD169	UL97	C592G	3.2													Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiae469/7762822	doi.org/10.1093/infdis/jiae469	Recombinant BAC 	SEAP			31/10/2024	OJCharles		AD169	A
1957	HCMV	AD169	UL97	H411Y										17				Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiae469/7762822	doi.org/10.1093/infdis/jiae469	Recombinant BAC 	SEAP			31/10/2024	OJCharles		AD169	A
1958	HCMV	AD169	UL97	G343A	7.9									272				Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiae469/7762822	doi.org/10.1093/infdis/jiae469	Recombinant BAC 	SEAP	UL97	H411Y	31/10/2024	OJCharles		AD169	A
1964	HCMV	AD169	UL97	V466G	2.9		1.2	1		0.5								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA			11/08/2025	OJCharles		AD169	A
1965	HCMV	AD169	UL97	C603R	3.5		1.4	1.5		1.3								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA			11/08/2025	OJCharles		AD169	A
1966	HCMV	AD169	UL54	N408D	2.1		3	1.1		1.4								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA			11/08/2025	OJCharles		AD169	A
1967	HCMV	AD169	UL54	K500N	2.9		5.8	1.2		0.5								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA			11/08/2025	OJCharles		AD169	A
1968	HCMV	AD169	UL54	C539R	2.2		5	0.5		1.1								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA			11/08/2025	OJCharles		AD169	A
1969	HCMV	AD169	UL54	L545S	2		5.1	1.3		0.4								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA			11/08/2025	OJCharles		AD169	A
1970	HCMV	AD169	UL54	T552N	1.9		1.4	4.8		1.7								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA			11/08/2025	OJCharles		AD169	A
1971	HCMV	AD169	UL54	Q578L	2.6		1.9	3.2		0.9								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA			11/08/2025	OJCharles		AD169	A
1972	HCMV	AD169	UL54	S585A	1.2		1.7	3.6		1								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA			11/08/2025	OJCharles		AD169	A
1973	HCMV	AD169	UL54	V787L	2		1.8	2.9		1.4								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA			11/08/2025	OJCharles		AD169	A
1974	HCMV	AD169	UL54	L802M	2.1		1.6	3.6		0.7								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA			11/08/2025	OJCharles		AD169	A
1975	HCMV	AD169	UL54	V812L	2.2		3.5	1.1		1.9								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA			11/08/2025	OJCharles		AD169	A
1976	HCMV	AD169	UL54	T821I	2.7		1.5	2.9		1.1								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA			11/08/2025	OJCharles		AD169	A
1977	HCMV	AD169	UL54	P829S	3.7		1.2	0.9		0.5								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA			11/08/2025	OJCharles		AD169	A
1978	HCMV	AD169	UL54	L957F	2.1		1.7	1.8		1.4								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA			11/08/2025	OJCharles		AD169	A
1979	HCMV	AD169	UL54	N408D	2.4		1.8	2.9		1.9								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA	UL54	T552N	11/08/2025	OJCharles		AD169	A
1980	HCMV	AD169	UL54	K500N	2.3		2.8	2.8		0.7								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA	UL54	S585A	11/08/2025	OJCharles		AD169	A
1981	HCMV	AD169	UL54	N408D	2.3		2.3	3.5		0.9								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA	UL54	L957F	11/08/2025	OJCharles		AD169	A
1982	HCMV	AD169	UL54	L545S	3.2		4.1	1.8		1.8								In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	PRA	UL54	P829S	11/08/2025	OJCharles		AD169	A
1983	HCMV	AD169	UL56	V236M	1.4		1.2	0.6		20				1.1				In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	GLuc			11/08/2025	OJCharles		AD169	A
1984	HCMV	AD169	UL56	C325F	1.2		1.2	0.6		4337				1.2				In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	GLuc			11/08/2025	OJCharles		AD169	A
1985	HCMV	AD169	UL97	L337M	1.3		0.5	0.9		1				2.7				In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	GLuc			11/08/2025	OJCharles		AD169	A
1986	HCMV	AD169	UL97	F342S	16.5		0.8	1		1				35				In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	GLuc			11/08/2025	OJCharles		AD169	A
1987	HCMV	AD169	UL97	L397R	1.4		0.9	1		1.1				121				In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	GLuc			11/08/2025	OJCharles		AD169	A
1988	HCMV	AD169	UL97	T409M	0.9		0.8	1.1		1.2				83				In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	GLuc			11/08/2025	OJCharles		AD169	A
1989	HCMV	AD169	UL97	H411Y	0.4		0.6	0.4		1.2				20				In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	GLuc			11/08/2025	OJCharles		AD169	A
1990	HCMV	AD169	UL97	P521L	46		0.7	1.9		1				94				In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes	https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973	doi.org/10.1016/j.antiviral.2022.105328	Recombinant BAC 	GLuc			11/08/2025	OJCharles		AD169	A
1991	HCMV	AD169	UL54	E756K	1.9		3	3.9										Novel Method Based on â€œEn Passantâ€ Mutagenesis Coupled with aÂ GaussiaÂ Luciferase Reporter Assay for Studying the Combined Effects of Human Cytomegalovirus Mutations	https://journals.asm.org/doi/10.1128/jcm.01275-13	doi.org/10.1128/jcm.01275-13	Recombinant BAC 	GLuc			11/08/2025	OJCharles		AD169	A
1992	HCMV	AD169	UL97	A594V	8.2													Novel Method Based on â€œEn Passantâ€ Mutagenesis Coupled with aÂ GaussiaÂ Luciferase Reporter Assay for Studying the Combined Effects of Human Cytomegalovirus Mutations	https://journals.asm.org/doi/10.1128/jcm.01275-13	doi.org/10.1128/jcm.01275-13	Recombinant BAC 	GLuc			11/08/2025	OJCharles		AD169	A
1993	HCMV	AD169	UL97	A594V	10.8		2	4.1										Novel Method Based on â€œEn Passantâ€ Mutagenesis Coupled with aÂ GaussiaÂ Luciferase Reporter Assay for Studying the Combined Effects of Human Cytomegalovirus Mutations	https://journals.asm.org/doi/10.1128/jcm.01275-13	doi.org/10.1128/jcm.01275-13	Recombinant BAC 	GLuc	UL54	E756K	11/08/2025	OJCharles		AD169	A
1994	HCMV	AD169	UL97	H587Y	1.2													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
1995	HCMV	AD169	UL97	C592G	3.2													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
1996	HCMV	AD169	UL97	C603W	8.3													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
1997	HCMV	AD169	UL54	P522S	2.4													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
1998	HCMV	AD169	UL54	A987G	6.2													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
1999	HCMV	AD169	UL97	A440V	1.2													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2000	HCMV	AD169	UL97	A442G	12													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2001	HCMV	AD169	UL54	E315D	0.9													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2002	HCMV	AD169	UL54	F357L	1.2													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2003	HCMV	AD169	UL54	V377A	1.2													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2004	HCMV	AD169	UL54	P448S	1.2													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2005	HCMV	AD169	UL54	R512H	1.4													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2006	HCMV	AD169	UL54	C524R	1.2													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2007	HCMV	AD169	UL54	E530G	1.3													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2008	HCMV	AD169	UL54	D576G	1.3													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2009	HCMV	AD169	UL54	A635T	1.5													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2010	HCMV	AD169	UL54	P648S	1.2													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2011	HCMV	AD169	UL54	S649P	1.2													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2012	HCMV	AD169	UL54	V694I	1													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2013	HCMV	AD169	UL54	I837V	0.8													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2014	HCMV	AD169	UL54	L897P	0.9													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2015	HCMV	AD169	UL54	G993D	1.1													Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis	https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27	doi.org/10.1097/TP.0b013e3181fdd9d2	Recombinant BAC 	SEAP			11/08/2025	OJCharles		AD169	A
2016	HCMV	AD169	UL97	M460V	4.5													Analysis Of The Ul97 Phosphotransferase Coding Sequence In Clinical Cytomegalovirus Isolates And Identification Of Mutations Conferring Ganciclovir Resistance	https://academic.oup.com/jid/article-abstract/171/3/576/821679	doi.org/10.1093/infdis/171.3.576	Marker Transfer	PCR DNA hybridization assay			11/08/2025	OJCharles	Other mutations present but not characterised	AD169	O
2017	HCMV	AD169	UL97	A594V	11													Analysis Of The Ul97 Phosphotransferase Coding Sequence In Clinical Cytomegalovirus Isolates And Identification Of Mutations Conferring Ganciclovir Resistance	https://academic.oup.com/jid/article-abstract/171/3/576/821679	doi.org/10.1093/infdis/171.3.576	Marker Transfer	PCR DNA hybridization assay			11/08/2025	OJCharles	Other mutations present but not characterised	AD169	O
2018	HCMV	AD169	UL97	L595S	13													Analysis Of The Ul97 Phosphotransferase Coding Sequence In Clinical Cytomegalovirus Isolates And Identification Of Mutations Conferring Ganciclovir Resistance	https://academic.oup.com/jid/article-abstract/171/3/576/821679	doi.org/10.1093/infdis/171.3.576	Marker Transfer	PCR DNA hybridization assay			11/08/2025	OJCharles	Other mutations present but not characterised	AD169	O
2019	HCMV	Clinical isolate	UL97	M460V	10													Ganciclovir resistance mutations in UL97 and UL54 genes of Human cytomegalovirus isolates resistant to ganciclovir	https://pubmed.ncbi.nlm.nih.gov/15230476/		Isolated strain	PRA			14/08/2025	OJCharles	"High variation in ""WT"" reps - take absolute fold changes as a rough ballpark"	Clinical isolate	A
2020	HCMV	Clinical isolate	UL97	A594T	2.7													Ganciclovir resistance mutations in UL97 and UL54 genes of Human cytomegalovirus isolates resistant to ganciclovir	https://pubmed.ncbi.nlm.nih.gov/15230476/		Isolated strain	PRA			14/08/2025	OJCharles	"High variation in ""WT"" reps - take absolute fold changes as a rough ballpark"	Clinical isolate	A
2021	HCMV	Clinical isolate	UL97	A594T	3.1													Ganciclovir resistance mutations in UL97 and UL54 genes of Human cytomegalovirus isolates resistant to ganciclovir	https://pubmed.ncbi.nlm.nih.gov/15230476/		Isolated strain	PRA	UL54	P522S	14/08/2025	OJCharles	"High variation in ""WT"" reps - take absolute fold changes as a rough ballpark"	Clinical isolate	A
2022	HCMV	Clinical isolate	UL97	C603W	2													Ganciclovir resistance mutations in UL97 and UL54 genes of Human cytomegalovirus isolates resistant to ganciclovir	https://pubmed.ncbi.nlm.nih.gov/15230476/		Isolated strain	PRA			14/08/2025	OJCharles	"High variation in ""WT"" reps - take absolute fold changes as a rough ballpark"	Clinical isolate	A
2028	HCMV	Towne	UL54	D981del2	7		4	4										A Deletion Mutation in Region V of the Cytomegalovirus DNA Polymerase Sequence Confers Multidrug Resistance	https://academic.oup.com/jid/article-abstract/182/6/1765/916204	doi.org/10.1086/317618	Marker Transfer	PRA			14/08/2025	OJCharles		Towne	A
2032	HCMV	MMT	UL97	D605E	0.5													Single and multiple mutations in the human cytomegalovirus UL97 gene and their relationship to the enzymatic activity of UL97 kinase for ganciclovir phosphorylation	https://www.sciencedirect.com/science/article/abs/pii/S0166354209004239	10.1016/j.antiviral.2009.08.005	Marker Transfer	TK functional kinetic assay			18/08/2025	OJCharles	Kinetic slowdown factors from this paper correlate very well with resistance fold changes from others - assuming 1:1 correlation	MMT	A
2033	HCMV	MMT	UL97	M460V	8.3													Single and multiple mutations in the human cytomegalovirus UL97 gene and their relationship to the enzymatic activity of UL97 kinase for ganciclovir phosphorylation	https://www.sciencedirect.com/science/article/abs/pii/S0166354209004239	10.1016/j.antiviral.2009.08.005	Marker Transfer	TK functional kinetic assay			18/08/2025	OJCharles	Kinetic slowdown factors from this paper correlate very well with resistance fold changes from others - assuming 1:1 correlation	MMT	A
2034	HCMV	MMT	UL97	M460V	14													Single and multiple mutations in the human cytomegalovirus UL97 gene and their relationship to the enzymatic activity of UL97 kinase for ganciclovir phosphorylation	https://www.sciencedirect.com/science/article/abs/pii/S0166354209004239	10.1016/j.antiviral.2009.08.005	Marker Transfer	TK functional kinetic assay	UL97	A594P	18/08/2025	OJCharles	Kinetic slowdown factors from this paper correlate very well with resistance fold changes from others - assuming 1:1 correlation	MMT	A
2035	HCMV	MMT	UL97	A594P	3.2													Single and multiple mutations in the human cytomegalovirus UL97 gene and their relationship to the enzymatic activity of UL97 kinase for ganciclovir phosphorylation	https://www.sciencedirect.com/science/article/abs/pii/S0166354209004239	10.1016/j.antiviral.2009.08.005	Marker Transfer	TK functional kinetic assay			18/08/2025	OJCharles	Kinetic slowdown factors from this paper correlate very well with resistance fold changes from others - assuming 1:1 correlation	MMT	A
2036	HCMV	MMT	UL97	A594P	4													Single and multiple mutations in the human cytomegalovirus UL97 gene and their relationship to the enzymatic activity of UL97 kinase for ganciclovir phosphorylation	https://www.sciencedirect.com/science/article/abs/pii/S0166354209004239	10.1016/j.antiviral.2009.08.005	Marker Transfer	TK functional kinetic assay	UL97	D605E	18/08/2025	OJCharles	Kinetic slowdown factors from this paper correlate very well with resistance fold changes from others - assuming 1:1 correlation	MMT	A
2044	HCMV	AD169	UL97	L397R	2.6		2	1.3						171				Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet	https://www.sciencedirect.com/science/article/abs/pii/S1386653206002538	doi.org/10.1016/j.jcv.2006.07.010	Recombinant BAC 	SEAP			18/08/2025	OJCharles		AD169	A
2045	HCMV	AD169	UL97	M460V	8.2									0.4				Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet	https://www.sciencedirect.com/science/article/abs/pii/S1386653206002538	doi.org/10.1016/j.jcv.2006.07.010	Recombinant BAC 	SEAP			18/08/2025	OJCharles		AD169	A
2046	HCMV	AD169	UL97	A594V	10.4									2.2				Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet	https://www.sciencedirect.com/science/article/abs/pii/S1386653206002538	doi.org/10.1016/j.jcv.2006.07.010	Recombinant BAC 	SEAP			18/08/2025	OJCharles		AD169	A
2047	HCMV	AD169	UL97	C592G	3.9									1.4				Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet	https://www.sciencedirect.com/science/article/abs/pii/S1386653206002538	doi.org/10.1016/j.jcv.2006.07.010	Recombinant BAC 	SEAP			18/08/2025	OJCharles		AD169	A
2048	HCMV	AD169	UL97	L595S	8.6									1.8				Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet	https://www.sciencedirect.com/science/article/abs/pii/S1386653206002538	doi.org/10.1016/j.jcv.2006.07.010	Recombinant BAC 	SEAP			18/08/2025	OJCharles		AD169	A
2049	HCMV	AD169	UL54	A809V	2.1		1.8	4						0.4				Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet	https://www.sciencedirect.com/science/article/abs/pii/S1386653206002538	doi.org/10.1016/j.jcv.2006.07.010	Recombinant BAC 	SEAP			18/08/2025	OJCharles		AD169	A
2050	HCMV	AD169	UL54	del981-982	4.6		3.3	2.5						0.6				Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet	https://www.sciencedirect.com/science/article/abs/pii/S1386653206002538	doi.org/10.1016/j.jcv.2006.07.010	Recombinant BAC 	SEAP			18/08/2025	OJCharles		AD169	A
2051	HCMV	AD169	UL54	N408K	6.5		20	0.8						0.5				Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet	https://www.sciencedirect.com/science/article/abs/pii/S1386653206002538	doi.org/10.1016/j.jcv.2006.07.010	Recombinant BAC 	SEAP			18/08/2025	OJCharles		AD169	A
2052	HCMV	Towne	UL54	S291P				1.7										Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet	https://www.sciencedirect.com/science/article/abs/pii/S0166093405000236	doi.org/10.1016/j.jviromet.2005.01.005	Marker Transfer	Functional enzyme kinetic assay			18/08/2025	OJCharles		Towne	A
2053	HCMV	Towne	UL54	K415R				1.5										Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet	https://www.sciencedirect.com/science/article/abs/pii/S0166093405000236	doi.org/10.1016/j.jviromet.2005.01.005	Marker Transfer	Functional enzyme kinetic assay			18/08/2025	OJCharles		Towne	A
2054	HCMV	Towne	UL54	V715M				65										Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet	https://www.sciencedirect.com/science/article/abs/pii/S0166093405000236	doi.org/10.1016/j.jviromet.2005.01.005	Marker Transfer	Functional enzyme kinetic assay			18/08/2025	OJCharles		Towne	A
2055	HCMV	Towne	UL54	E756K				31										Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet	https://www.sciencedirect.com/science/article/abs/pii/S0166093405000236	doi.org/10.1016/j.jviromet.2005.01.005	Marker Transfer	Functional enzyme kinetic assay			18/08/2025	OJCharles		Towne	A
2056	HCMV	Towne	UL54	N495K				5										Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet	https://www.sciencedirect.com/science/article/abs/pii/S0166093405000236	doi.org/10.1016/j.jviromet.2005.01.005	Marker Transfer	Functional enzyme kinetic assay			18/08/2025	OJCharles		Towne	A
2083	HCMV	AD169	UL54	K805Q	0.8			0.3										Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity	https://journals.sagepub.com/doi/10.3851/IMP1565	doi.org/10.3851/IMP156	Marker Transfer	PRA			18/08/2025	OJCharles		AD169	A
2084	HCMV	AD169	UL54	T821I	5.3			23.3										Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity	https://journals.sagepub.com/doi/10.3851/IMP1565	doi.org/10.3851/IMP156	Marker Transfer	PRA			18/08/2025	OJCharles		AD169	A
2085	HCMV	AD169	UL54	K805Q	2		2	2	2					2				Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity	https://journals.sagepub.com/doi/10.3851/IMP1565	doi.org/10.3851/IMP156	Marker Transfer	Functional enzyme kinetic assay			18/08/2025	OJCharles		AD169	A
2086	HCMV	AD169	UL54	T821I	5.5		5.5	5.5	5.5					5.5				Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity	https://journals.sagepub.com/doi/10.3851/IMP1565	doi.org/10.3851/IMP156	Marker Transfer	Functional enzyme kinetic assay			18/08/2025	OJCharles		AD169	A
2087	HCMV	Clinical isolate	UL54	L501F	22		10											Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir	https://link.springer.com/article/10.1007/s007050050072	doi.org/10.1007/s007050050072	Isolated strain	PRA			18/08/2025	OJCharles		91-7S	A
2088	HCMV	AD169	UL97	C480R											9.2			Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions	https://journals.asm.org/doi/full/10.1128/aac.01726-13	doi.org/10.1128/aac.01726-13	Lab derived mutant	PRA			26/08/2025	OJCharles		AD169	A
2089	HCMV	AD169	UL97	del617											18			Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions	https://journals.asm.org/doi/full/10.1128/aac.01726-13	doi.org/10.1128/aac.01726-13	Lab derived mutant	PRA			26/08/2025	OJCharles		AD169	A
2090	HCMV	AD169	UL97	D456N											4.6			Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions	https://journals.asm.org/doi/full/10.1128/aac.01726-13	doi.org/10.1128/aac.01726-13	Lab derived mutant	PRA			26/08/2025	OJCharles		AD169	A
2091	HCMV	Towne	UL54	V781I	4.7			4.2										Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity	https://www.sciencedirect.com/science/article/pii/S1386653201001603	doi.org/10.1016/S1386-6532(01)00160-3					07/09/2025	OJCharles	Given resistance factors in other papers I believe the 2 recombinants in this paper have been mixed up		O
2093	HCMV	AD169	UL56	V236M	1.4		0.9	0.6	0.9	31								Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes	https://journals.asm.org/doi/10.1128/aac.01044-17	doi.org/10.1128/aac.01044-17	Recombinant BAC 	Gluc reporter assay			31/12/2025	OJCharles		AD169	A
2094	HCMV	AD169	UL54	E756K	7.1		1.8	3.5	2.8	1.4								Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes	https://journals.asm.org/doi/10.1128/aac.01044-17	doi.org/10.1128/aac.01044-17	Recombinant BAC 	Gluc reporter assay			46022	OJCharles		AD169	A
